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ABSTRACT  
Acute lymphocytic leukemia (ALL) is the most common type of childhood cancer accounting for 
approximately 25% of cancers diagnosed in children less than 20 years of age. It originates in the 
bone marrow and prevents the normal manufacture of red blood cells, white blood cells and 
platelets. A poor nutritional status is frequently observed in children with ALL at the time of 
diagnosis and during treatment which may result in protein energy malnutrition if nutrition 
intervention is delayed. This retrospective study aims to assess the nutritional status of children 
newly diagnosed with Acute Lymphoblastic Leukemia (ALL) using 20 case studies between 1 
January 2013 and 31 December 2014 from Sheikh Khalifa Medical City (Abu Dhabi, UAE), in 
order to develop an appropriate nutritional support protocol for pediatric ALL patients treated at 
this institution.    
Study Design 
A retrospective descriptive case study design was used. The study population consisted of 20 
electronic medical records of patients aged between 1-14 years who were newly diagnosed with 
Acute Lymphoblastic Leukemia (ALL) and admitted to Sheikh Khalifa Medical City for 
treatment during the period 1 January 2012 and 31 Dec 2014.  
Data Collection 
Identification of suitable participants began through a review of each potential study participant`s 
electronic medical record. Data was collected and recorded on a data collection form (Appendix 
III) from the electronic medical record for each suitable participant for the following at 
admission and during the full duration of all phases of cancer treatment namely induction, 
consolidation, interim maintenance, delayed intensification and maintenance. The data collected 
comprised of the following: age, gender, date of diagnosis, symptoms on diagnosis, the cancer 
diagnosis (type and subtype), anthropometric measurements (weight, length/ height, head 
circumference), biochemical values (visceral proteins, blood glucose levels, hemoglobin, 
hematocrit, lymphocyte count), clinical assessment (stomatitis, anemia, mucositis), diet history 
(home feeding regimes; consumption of daily requirements; food preferences – types, textures; 
food allergies, food intolerances; food aversions; use of oral nutritional supplements; treatment-
related side-effects; systemic related side-effects (nausea; vomiting; diarrhea; anorexia; appetite 
changes; taste changes; physical activity level; depression), dietary requirements (age and gender 
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related nutritional requirements for energy, protein, fat and fluids) and indications for nutritional 
support (oral feeding; enteral feeding; parenteral feeding).  
Analysis of Results 
The weights and length/ heights of participants recorded in the electronic medical records were 
converted to z-scores on the World Health Organization growth charts. The diet prescription of 
nutritional intervention was interpreted in comparison to the biochemical indices, anthropometric 
status and dietary intake of each participant. All the data involving changes in anthropometrics, 
biochemistry, diet history and nutritional interventions from each case study (from diagnosis and 
through all stages of treatment) was screened and compared with reference values in the context 
of the age and sex of the child. Evidence based nutritional guidelines were used to document the 
outcomes of the medical nutrition treatment provided in order to develop a nutrition support 
protocol for children with Acute Lymphoblastic Leukemia at Sheikh Khalifa Medical City.  
Results 
The results showed that weight loss expressed as a percentage of body weight provided a more 
accurate estimate of the true significance of weight loss in subjects undergoing cancer treatment 
(chemotherapy) for ALL. A weight loss of greater than 5% of body weight over a period of one 
month is considered a sign of nutritional deprivation even if the subject is not classified as 
undernourished by anthropometric parameters. Subjects experienced the highest weight loss 
during the consolidation phase and interim maintenance phases of treatment.  
Conclusion 
It can therefore be concluded that pediatric subjects on cancer treatment for ALL at SKMC and 
receiving nutritional support underwent changes in nutritional status as manifest by a reduction 
in more than 5% of their body weight during three phases of treatment namely induction, 
consolidation and interim maintenance. An appropriate nutrition support protocol was developed 
based on the results and experience obtained from this study for pediatric ALL patients treated at 
SKMC.    
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1.1.  INTRODUCTION 
Acute lymphocytic leukemia (ALL) is the most common type of childhood cancer accounting for 
approximately 25% of cancers diagnosed in children less than 20 years of age (Al-Mulla et al, 
2014; Zhanga et al, 2014; Owens et al, 2013). It originates in the bone marrow and is 
characterized by the continuous multiplication of malignant white blood cells which results in an 
excess of lymphoblasts in the bone marrow and the peripheral blood. This prevents the normal 
manufacture of red blood cells, white blood cells and platelets (Children’s Oncology Group, 
2015; Owens et al, 2013) and this deviation from the normal hematopoietic processes leads to 
bicytopenia and leukocytosis and/or pancytopenia and aplastic anemia in patients at initial 
diagnosis for ALL (Children’s Oncology Group, 2015). A poor nutritional status is frequently 
observed in children with ALL at the time of diagnosis and during treatment which may result in 
protein energy malnutrition if nutritional intervention is delayed.  
1.2. RATIONALE OF THE STUDY 
In the Middle East, leukemia is reported to be one of the ten most common malignancies and is 
the major form of pediatric cancer which accounts for 39.4% of pediatric cancer diagnosis. 
Leukemia in Middle Eastern countries was found to occur in 36% of subjects in the 0-10 year 
age group; 16 % in subjects in the 10-20 year age group and in 19% of subjects in the 20-30 year 
age groups (Tadmouri et al, 2010). In the United Arab Emirates the geographic distribution of 
leukemia cases was reported as follows: 25 % were from Abu Dhabi; 20.8 % from Al Ain and 
17.7 % from Sharjah (Tadmouri et al, 2010). Pediatric ALL is said to be the most common 
malignancy in the Middle East, with a peak age range of 3-6 years which is similar to the age 
range reported in western countries (Al-Mulla et al, 2014). The incidence of ALL in males was 
found to be slightly higher than females with a gender ratio of males: females being 1.4: 1.  
1.3. PROBLEM STATEMENT 
In the United Arab Emirates (UAE), the incidence of cancer is the third leading cause of death in 
the total population, following cardiovascular disease and accidents (Badrinath et al, 2004). 
Leukemia is the third most common cancer especially amongst females and is the most common 
form of pediatric cancer, accounting for 39.4%. Aggressive treatment modalities like 
chemotherapy and radiation therapy impact negatively on the nutritional status of a child with 
Acute Lymphoblastic Leukemia (ALL) resulting in a poor nutritional status which is frequently 
observed at the time of diagnosis and during treatment. Adequate nutrition is therefore an 
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important concern in children with ALL as a good nutritional status helps them cope better with 
the side-effects of anticancer therapy which has a negative impact on their nutritional intake  
1.4. AIM OF THE STUDY 
This retrospective study aims to assess the nutritional status of children newly diagnosed with 
Acute Lymphoblastic Leukemia (ALL) using 20 case studies between 1 January 2013 and 31 
December 2014 from Sheikh Khalifa Medical City (Abu Dhabi, UAE), in order to develop an 
appropriate nutritional support protocol for pediatric ALL patients treated at this institution.    
1.5. SPECIFIC OBJECTIVES   
1.5.1. To assess the nutritional status of children newly diagnosed with ALL by using 
anthropometric measurements (weight, length/height, head circumference and BMI), 
biochemical data (visceral proteins, blood glucose levels, hemoglobin, hematocrit, lymphocyte 
count) and diet history records (home feeding regimes, food preferences – types, textures, 
feeding environment food allergies, food intolerances) at diagnosis. 
1.5.2. To assess the nutritional status of children newly diagnosed with  ALL by using 
anthropometric measurements (weight, length/height, head circumference and BMI), 
biochemical data (visceral proteins, blood glucose levels, hemoglobin, hematocrit, lymphocyte 
count) and diet history records (home feeding regimes, food preferences – types, textures, 
feeding environment food allergies, food intolerances) at the start and end of induction 
chemotherapy. 
1.5.3. To assess the nutritional status of children newly diagnosed with  ALL by using 
anthropometric measurements (weight, length/height, head circumference and BMI), 
biochemical data (visceral proteins, blood glucose levels, hemoglobin, hematocrit, lymphocyte 
count) and diet history records (home feeding regimes, food preferences – types, textures, 
feeding environment food allergies, food intolerances) at the start and end of consolidation 
chemotherapy. 
1.5.4. To assess the nutritional status of children newly diagnosed with ALL by using 
anthropometric measurements (weight, length/height, head circumference and BMI), 
biochemical data (visceral proteins, blood glucose levels, hemoglobin, hematocrit, lymphocyte 
count) and diet history records (home feeding regimes, food preferences – types, textures, 
feeding environment food allergies, food intolerances) at the start and end of interim 
maintenance chemotherapy. 
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1.5.5. To assess the nutritional status of children newly diagnosed with ALL by using 
anthropometric measurements (weight, length/height, head circumference and BMI), 
biochemical data (visceral proteins, blood glucose levels, hemoglobin, hematocrit, lymphocyte 
count) and diet history records (home feeding regimes, food preferences – types, textures, 
feeding environment food allergies, food intolerances) at the start and end of delayed 
intensification chemotherapy. 
1.5.6. To assess the nutritional status of children newly diagnosed with  ALL by using 
anthropometric measurements (weight, length/height, head circumference and BMI), 
biochemical data  (visceral proteins, blood glucose levels, hemoglobin, hematocrit, lymphocyte 
count) and diet history records (home feeding regimes, food preferences – types, textures, 
feeding environment food allergies, food intolerances) at the start and end of maintenance 
chemotherapy. 
1.5.7. To develop an appropriate nutrition support protocol for pediatric patients newly 
diagnosed with ALL at Sheikh Khalifa Medical City (Abu Dhabi, UAE) by screening all the data 
involving changes in anthropometrics, biochemistry, diet history and nutritional interventions, 
from each case study, from diagnosis and through all stages of treatment (induction, 
consolidation, interim maintenance, delayed intensification and maintenance) and comparing this 
data with reference values in the context of the age and sex of the child as well as evidence based 
nutritional guidelines. This was done to determine whether the nutrition interventions provided 
during each treatment phase had an impact on the nutritional status of each case study. These 
results were then used to develop a nutrition support protocol for children with Acute 
Lymphoblastic Leukemia at SKMC. This protocol will serve to standardize the feeding practice 
of children with ALL in order for them to achieve their nutritional goals during treatment.   
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1.6. LAYOUT  
The layout of this write up is as follows: 
Chapter 2: Literature Review  
Chapter 3: Methodology 
Chapter 4: Results 
Chapter 5: Discussion 
Chapter 6: The development of a nutrition support protocol 
Chapter 7: Conclusion and Recommendations 
Chapter 8: Limitations of the Study 
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2.1. Introduction  
Acute lymphocytic leukemia (ALL) is the most common type of childhood cancer accounting for 
approximately 25% of cancers diagnosed in children less than 20 years of age (Al-Mulla et al, 
2014; Zhanga et al, 2014; Owens et al, 2013). It originates in the bone marrow and is 
characterized by the continuous multiplication of malignant white blood cells which results in an 
excess of lymphoblasts in the bone marrow and the peripheral blood. This prevents the normal 
manufacturing of red blood cells, white blood cells and platelets (Children’s Oncology Group, 
2015; Owens et al, 2013). This deviation from the normal hematopoietic processes leads to 
bicytopenia and leukocytosis and or pancytopenia and aplastic anemia in patients at initial 
diagnosis for ALL (Children’s Oncology Group, 2015).  
The most common symptoms of childhood ALL include lethargy, fatigue, bone pain and a loss 
in appetite (Salim et al, 2014). Bone pain which is a common symptom of childhood ALL occurs 
as a result of leukemic infiltration in the periosteum resulting in osteopenia (Children’s 
Oncology Group, 2015). 
2.2. Incidence of Acute Lymphoblastic Leukemia 
In the Middle East, leukemia is reported to be one of the ten most common malignancies and is 
the major form of pediatric cancer which accounts for 39.4% of pediatric cancer diagnosis. 
Leukemia in Middle Eastern countries was found to occur in 36% of subjects in the 0-10 year 
age group; 16 % in subjects in the 10-20 year age group and in 19% of subjects in the 20-30 year 
age group (Tadmouri et al, 2010). In the United Arab Emirates, the geographic distribution of 
leukemia cases was reported as follows: 25 % were from Abu Dhabi; 20.8 % from Al Ain and 
17.7 % from Sharjah (Tadmouri et al, 2010). Pediatric ALL is said to be the most common 
malignancy in the Middle East, with a peak age range of between 3-6 years of age which is 
similar to the age range reported in western countries (Al-Mulla et al, 2014). The incidence of 
ALL in males was found to be slightly higher than females with a gender ratio of males: females 
being 1.4: 1.  
In their study on 1150 ALL patients in the Middle East, Al-Mulla et al (2014) found the most 
common symptom at diagnosis to be pallor, followed by fever. Bone pain was reported in 39.6% 
of the patients. Testicular involvement was clinically suspected in 26.7% but was confirmed in 
only 2.4% of the male patients. On presentation lymphadenopathy was confirmed in 62.6%; 
splenomegaly in 60.8% and hepatomegaly in 59.5% of the patients (Al-Mulla et al, 2014). Some 
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studies have suggested that the high rate of consanguinity in the Arab population could account 
for the increased incidence of leukemia in children however the results of other studies have 
been inconsistent (Tadmouri et al, 2010). 
2.3. The classification of childhood ALL  
In children, the type and subtype of leukemia is determined by testing samples of blood and bone 
marrow which plays a major role in determining the treatment options and predicts the prognosis 
of the disease (American Cancer Association, 2015). Leukemic cells often spread to other organs 
of the body such as the liver, spleen, lymph nodes, testes or central nervous system and if this 
should happen, the treatment has to be more intense in order to destroy the malignant cells 
(American Cancer Association, 2015).  
ALL is classified according to the type of lymphocyte (B cell or T cell) the leukemic cells are 
found in and the degree of maturity of the cells. The subtypes of ALL are named as follows: 
(American Cancer Association, 2015) 
2.3.1 B-cell ALL  
B cell ALL starts in B cells and is found in 80-85% of children with ALL. 
2.3.1.1. Early pre-B ALL is found in about 10% of cases. 
2.3.1.2. Common ALL is found in about 50% of cases 
2.3.1.3. Pre-B ALL is found in about 10% of cases. 
2.3.1.4. Mature B-cell ALL which is also known as Burkitt leukemia is rare accounting for only 
2-3% of cases and is treated differently from most leukemias.   
2.3.2. T-cell ALL 
T-cell ALL occurs in 15-20% of children with ALL and is more common in boys than girls. It 
mainly affects older children than B-cell ALL and sometimes causes breathing problems by 
affecting the thymus gland and may spread to the cerebrospinal fluid. 
2.3.2.1. Pre-T ALL is found in about 10% of cases. 
2.3.2.2. Mature T-cell ALL is found in about 15-20% of cases,    
Research done on 1150 Middle Eastern ALL patients by Al-Mulla et al (2014) found that 84.2% 
were classified as having B-cell involvement; 14.8% was classified as having T -cell 
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involvement and 11% showed mature B-cell involvement. In addition most of the patients did 
not have CNS involvement (Al-Mulla et al, 2014). 
2.4. The etiology and risk factors for ALL in children 
The etiologic factors contributing to the development of acute lymphoblastic leukemia (ALL) 
has not been completely established however it has been linked to a few strong risk factors such 
as birthweight (Tower and Spector, 2007); the mode of feeding (breastfeeding and formula 
feeding) (Schraw et al, 2014); gender (Gholami et al, 2013); maternal diet (Petridou et al, 2005); 
being an identical twin (Cancer Association, 2015); radiation exposure (Amitay and Keinan-
Boker, 2015) and Trisomy 21 (Downs syndrome) (Inaba et al, 2013; Whitlock et al, 2005).  
2.4.1. Birthweight: several studies have found a positive association between high birth weights 
(usually defined as > 4 kg) and the risk of developing childhood leukemia (Tower and Spector, 
2007). A study conducted by Hjalgrim et al (2003) on 10 282 cases found that children who 
weighed more than 4 kg at birth had a 26% higher risk of developing ALL and this trend risk for 
developing ALL increased by 14% for every 1 kg rise in birthweight (Tower and Spector, 2007 
citing Hjalgrim et al, 2003). Several consequent studies have firmly established the association 
between accelerated intrauterine growth and ALL (Schraw et al, 2014).  A proposed mechanism 
for this is the action of insulin-like growth factor 1 (IGF-1) which is a peptide produced in the 
liver and which also functions to promote growth in many cellular processes within the human 
body. High levels of IGF-1 have been associated with a high birth weight in infants. An 
increased birthweight has been found to produce an increased number of stem cells which can 
undergo malignant transformation therefore predisposing an infant to a higher risk of developing 
childhood leukemia (Tower and Spector, 2007). It has also been postulated that IGF-1 might 
stimulate the growth of cells that already have preleukemic genetic abnormalities. 
2.4.2. Breastfeeding: The World Health Organization (Schraw et al, 2014) and The American 
Academy of Pediatrics (Academy of Nutrition and Dietetics, 2015) recommend exclusive 
breastfeeding for the first 6 months of an infant’s life in order to achieve optimal growth, 
development and health. There have been several published studies to examine a possible 
relationship between being breastfed and childhood leukemia. The most recent meta-analysis 
published on this topic in 2007 found that breastfeeding for more than 6 months of age lowered 
the risk of a child developing ALL in childhood by 20% (Amitay and Keinan-Boker, 2015 citing 
Ip et al, 2007). Breastfed infants were also found to have a greater number of natural killer cells 
and the acid pH of the stomach of breastfed infants was found to promote the formation of 
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human alpha-lactalbumin made lethal to tumor cells (HAMLET) which is a protein-lipid 
complex that induces apoptosis-like death in tumor cells and leaves fully differentiated cells 
unaffected (Amitay and Keinan-Boker, 2015). 
2.4.3. Formula feeding:  Cow`s milk and cow`s milk based formula feeds have been shown to 
elevate insulin- like growth factor 1 (IGF-1) levels which could impact on leukemogenesis (the 
development of leukemia). `High IGF-1 exposure has been directly associated with the increased 
risk of ALL` (Schraw et al, 2014). Research by Schraw et al (2014) on 142 cases of ALL 
(between the ages of 1 and < 14 years old) found the duration of formula feeding and 
introduction of solids with each additional month of age increased the odds of developing ALL. 
A limitation to this study was the absence of data on IGF-1 levels to accompany the infant 
feeding data. 
2.4.4. Gender: ALL is slightly more common in males than females though the reason for this is 
unknown (Gholami et al, 2013). 
2.4.5. Maternal Diet: Research by Petridou et al (2005) reported a lower risk for ALL in 
children (12- 59 months) whose mothers consumed a healthy and traditionally Mediterranean 
diet (a high intake of vegetables, legumes, fruit, fish, cereals, olive oil and a low intake of 
saturated fat, meat and meat products, sugars and syrups) during pregnancy. This study also 
positively associated maternal age at birth with ALL risk in infants. The risk of childhood ALL 
has been shown to be significantly higher in children who are born to parents that are older. 
2.4.6. Identical twins: an individual who has an identical twin who develops ALL before the age 
of six years of age has an increased risk of developing ALL. If an identical twin develops ALL 
within the first few months of life, the other twin is almost always found to develop the same 
type of leukemia (Cancer Association, 2015).  
2.4.7. Radiation exposure: being exposed to high levels of radiation is a risk factor for ALL. 
Treating cancer with radiation therapy also increases the risk of leukemia and the risk is said to 
be higher for both radiation and chemotherapy which are both used in the treatment of cancer 
(Amitay and Keinan-Boker, 2015). 
2.4.8. Trisomy 21 or Downs syndrome: children with Downs syndrome have a 10 to 20 fold 
increased risk in developing ALL between the ages of 1-4 years old (Inaba et al, 2013; Whitlock 
et al, 2005) with ALL occurring in 1 in 300 children with Downs syndrome versus 1 in 3500 
children without Downs syndrome (Maloney, 2011 citing Robertson, 1992 and Lange, 2000). In 
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a large cohort study conducted by Whitlock et al (2005) children with ALL and Downs’s 
syndrome were also found to have lower platelet count coupled with a lower incidence of 
splenomegaly and lymphadenopathy and a higher hemoglobin level at diagnosis than children 
with ALL without Downs Syndrome. A review by Maloney (2011) found a greater incidence in 
remission induction failure in Downs syndrome ALL patients than non- Downs syndrome ALL 
patients. In the United Kingdom ALL trials found increased mortality in Downs syndrome ALL 
patients during induction; post remission consolidation; delayed intensification and during the 
third year of maintenance treatment in boys (Maloney, 2011).   
2.5. The treatment of pediatric ALL 
At diagnosis, risk groups are used to classify ALL instead of stages. The risk classification of 
childhood ALL is described as follows (Children’s Oncology Group, 2015): 
Standard risk ALL: includes children with a white blood cell count of less than 50 000/ 
microliter at diagnosis. 
High risk ALL: includes children with a white blood cell count equal to or greater than 50 000/ 
microliter at diagnosis. 
Treatment is based on the risk group and could span around 2-3 years. The treatment regimens 
currently in use to treat childhood ALL is aimed at disrupting and destroying the growth and 
division of cancer cells. The treatment is systemic which causes damage to healthy cells in the 
skin, hair follicles, mucus membranes, reproductive system and the gastrointestinal tract 
resulting in hair loss (alopecia) which includes loss of body hair, eyebrows and eyelashes; 
malabsorption; mucositis and a loss in taste (Chan, 2007). Patients receive high doses of 
chemotherapy without much break between cycles in order to induce remission (Owens et al, 
2013). 
Chemotherapy treatment protocols are based on the following factors (Children’s Oncology 
Group, 2015):  
 The age of the patient at diagnosis. 
 The white blood cell (WBC) count at diagnosis: children with WBC count greater than  
50 000 require more aggressive treatment. 
 Subtype of leukemia: `B-cell precursor` is the most common type and `T-cell` is a less 
common type. 
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 Central nervous system leukemia: children with leukemia cells in the spinal fluid at 
diagnosis require more aggressive treatment.    
 Testicular leukemia: this is common in 1-2% of boys with leukemia. 
 Chromosomal alterations in the leukemia cell: these abnormalities affect the type of 
treatment. 
 Response to therapy: the efficacy of the treatment is measured by counting the percentage 
of leukemia cells in the bone marrow at various intervals during the first month of 
therapy. Children who show poor response to treatment may require more aggressive 
treatment. 
ALL treatment protocols are divided into 4 phases namely: (Children`s Oncology Group, 2015) 
Induction: during this phase which usually lasts 4 weeks, children receive a combination of 3 or 
4 drugs either by mouth, intravenously or into the spinal fluid in order to destroy leukemia cells 
and allow normal blood cells to develop. Almost 98% of children with ALL enter remission after 
the induction phase.   
Consolidation: the duration of this phase is between 12-16 weeks and drugs different to those 
used during the induction phase are administered to patients either orally or intravenously. 
Delayed intensification: this cycle lasts 8 weeks and is aimed at preventing the leukemia from 
returning. 
Maintenance: this final stage of treatment lasts between 2-3 years and is less aggressive than the 
previous phases in that it mostly consists of oral medications given at home. 
Over the past decade the use of advanced multimodality treatments in children with ALL has 
produced an estimated 70% cure rate (Lughetti et al, 2012) and an 85% (5 year event free) 
survival rate (Chan, 2007). Cancer treatment toxicity is a major limitation causing frequent dose 
limitations and interruptions in treatment schedules (Chan, 2007).  
2.6. Nutrition screening of children with ALL 
Malnutrition is a serious concern for children with cancer. Nutrition screening and assessment is 
therefore vital to detect and manage cancer related nutritional problems. Nutrition screening is a 
simple, cost effective process carried out by health care staff at first contact with the patient in 
order to identify and assess patients at risk for malnutrition or who are malnourished to ensure 
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quick referral to a dietitian or nutrition support team for further nutritional assessment 
(McCarthy et al, 2012). 
There is several nutrition screening tools in use for a pediatric setting, with the most commonly 
used screening tools being The Pediatric Subjective Global Assessment (PSGA); The STAMP 
Tool and The Pediatric Yorkhill Malnutrition Screening (PYMS) and The Nutrition Screening 
Tool for Childhood Cancer (SCAN) (Murphy et al, 2015).  
2.6.1. The Pediatric Subjective Global Assessment (PSGA) 
The pediatric subjective global assessment is a comprehensive questionnaire comprised of   
information on a child`s physical examination; recent anthropometric measures; weight history; 
dietary intake (type, volume, frequency, rating of appetite changes in feeding or eating problems 
and dietary restrictions);  frequency and duration of gastrointestinal symptoms (loss of appetite, 
vomiting, diarrhea, constipation, stomach pain and nausea) and laboratory tests (for nutritional 
proteins) (Secker and Jeejeebhoy, 2007).  This tool when applied along with the Pediatric 
Yorkhill Malnutrition Screening on 247 subjects in the United Kingdom was found to have a 
high specificity and positive predictive value however its sensitivity was low (Moeeni and Day, 
2012 citing Gerasimidis et al, 2010). However it was also found to be lengthy, time-consuming, 
expensive and difficult to apply to all patients, this resulted in this tool being considered `more of 
an assessment tool, able to identify children with established malnutrition rather than a screening 
tool` (Moeeni and Day, 2012).  
2.6.2. The STAMP Tool  
The STAMP tool makes use of 5 simple steps which considers 3 elements namely clinical 
diagnosis; nutritional intake and anthropometric measurements of hospitalized pediatric patients 
between the ages of 2-16 years. Each element is assigned a score and the total score is supposed 
to indicate a low or moderate or high risk of malnutrition (McCarthy et al, 2008). Patients with a 
high risk score are referred to the dietitian and / or nutrition support team for nutrition 
intervention; patients with a medium risk score are monitored and reassessed after 3 days and 
those with a low risk are reassesses weekly. This tool has been validated in one study which 
included 89 subjects, of which 20% were classified as being at nutritional risk. More studies are 
however needed to further validate this tool within a clinical setting (Moeeni and Day, 2012). 
Literature by Selwood et al (2010) found the STAMP tool to score all children receiving cancer 
treatment as being `high risk` due to the scoring system used. 
 
 
 
 
  
14 
2.6.3. The Pediatric Yorkhill Malnutrition Screening (PYMS) 
The Pediatric Yorkhill Malnutrition Screening (PYMS) has been described by Gerasimidis et al 
(2010) as `an inexpensive and simple tool effective in identifying pediatric patients at risk for 
malnutrition and nutritionally related complications`. It assesses BMI, history of recent weight 
loss, changes in the nutritional intake of a child and the effect of the present medical diagnosis on 
the nutritional status of the child and it requires an accurate weight to be taken on the day on 
which the patient is screened (Gerasimidis et al, 2010). `The accuracy of the tool was assessed 
by two research dietitians who compared the nursing screening results with a full dietetic 
assessment, anthropometry and body composition measurements however the tool failed to 
include a specific question regarding previous underlying disease or chronic conditions` (Moeeni 
and Day, 2012). 
2.6.4. The nutrition screening tool for childhood cancer (SCAN) 
The nutrition screening tool for childhood cancer (SCAN), is a simple, practical, quick and valid 
screening tool which can be utilized to identify the need for nutritional intervention in children 
with cancer (up to the age of 18 years old) (Murphy et al, 2015). The tool consists of 6 questions 
with each question assigned a score of 1-2. The score allocated to each question determines the 
nutritional risk of the patient (Murphy et al, 2015). SCAN was evaluated against the pediatric 
subjective global assessment tool and a score of greater than or equal to 3 had 100% sensitivity 
and 39% specificity for detecting chronically malnourished children with cancer. ` The SCAN 
cutoff of greater than or equal to 3 was determined to be the ideal cut-off as no child with 
malnutrition will go undetected `(Murphy et al, 2015). It also utilizes information that is readily 
available and simple to use which makes it easy and quick to administer, reliable and consistent 
with low false positive or false negative findings. However the limitation of the SCAN tool is its 
inability to detect patients at risk for obesity during cancer treatment (Murphy et al, 2015). 
The selection criteria for a screening tool include the following:  
(a) Quick and efficient.  
(b) Simple to use and user –friendly to patients and healthcare staff (Gerasimidis et al, 2010). 
(c) Validity – the tools ability to differentiate between those `who are malnourished`, `at risk 
for malnutrition` and those `not at risk for malnutrition` (Moeeni and Day, 2012). 
(d) Reliability – which patient groups it is appropriate for? ; does it produce a consistent 
result if different people use it? (Moeeni and Day, 2012). 
 
 
 
 
  
15 
(e) Inexpensive – easy to implement. Equipment needed for implementation is available  
(f) Has an acceptable level of sensitivity and specificity and positive and negative predictive 
values. 
At Sheikh Khalifa Medical City (SKMC) the nutrition screening tool currently incorporated into 
the electronic pediatric patient chart is composed of 7 questions requiring a yes or no answer. 
The questions are as follows: unintentional weight loss within the past 3 months; reduced dietary 
intake in the last week; is the patient severely ill (confined to bed due to severe illness / 
scheduled for major surgery); does the patient look underweight? ; impaired nutritional status 
based on the oral intake of the patient in the past 3 or 2 or 1 month; severity of disease (hip 
fracture, COPD, chronic hemodialysis, diabetes, oncology, major abdominal surgery, 
pneumonia, head injury, bone marrow transplant, ICU patient with assisted ventilation and 
inotropic drugs). If the score is more than 2 a dietitian consult is generated by the system. If the 
score is between 0-1 the patient is rescreened in 7 days. This tool has not been validated for use 
in the pediatric population which means that a number of pediatric patients at `risk for 
malnutrition` are not effectively identified and/or referred for further nutritional intervention. 
This therefore impacts on the treatment of malnutrition which lengthens hospital stay; decreases 
wound healing and can possibly increase mortality in patients. 
2.7. Nutritional assessment of children with ALL 
Adequate nutrition is an important concern in children with ALL as a good nutritional status 
helps them cope better with the side-effects of cancer therapy by decreasing their risk of 
developing infections which can have a negative impact on their quality of life and survival.   
Nutritional status is defined as the extent to which nutrients are available and utilized by the 
body to meet metabolic demands to maintain health and promote growth (Shaw and Lawson, 
2007). An inadequate intake of nutrients at any time during childhood may impact on the growth 
and development of a child (Ladas et al, 2005). Current methods of assessing the nutritional 
status of children involve a combination of objective anthropometry, biochemical and 
immunologic measurements, clinical assessment and diet history (Nieuwoudt, 2011; Mosby et al, 
2009). The A; B; C; and D of the nutritional assessment process includes the following:    
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2.7.1. Anthropometric measurements 
Anthropometric measurements are rapid, inexpensive and non-invasive to obtain. In infants and 
children the most sensitive measurements of growth are weight, length/height, head 
circumference and body mass index (BMI). These measurements are commonly plotted on 
growth curves (against established reference data and adjusted for age) to monitor growth, detect 
growth abnormalities and accurately assess the nutritional status of infants and children (Collins 
et al, 2010).  
2.7.1.1. Weight: it is an indicator of current health and nutritional status and can be influenced by 
a patient`s body composition, fluid status, medication, organ enlargement or tumor mass. When 
plotted on a growth chart, the weight-for-age of a child is indicative of a child`s weight 
compared with other children of the same age and gender. It is also useful for tracking weight 
gain in infants and children, as well as, to explain changes in weight for length or BMI for age. 
Weight-for-age cannot be used to classify a child as `underweight or overweight`. It is more 
appropriate to use weight for length (in infants and children under the age of two years old) or 
weight for height (in children above the age of two years old) to identify underweight, 
overweight or within normal limits. (Pediatric Nutrition Reference Guide, 2013). Weight gain in 
children is often described in terms of the amount of weight a child has gained over a given 
period of time, also known as velocity of weight gain. Unintentional weight loss in children is 
often indicative of health and /or nutritional problems (Pediatric Nutrition Reference Guide, 
2013).  
 
In children, growth depends on a sustained increase in fat and lean body mass and an increased 
demand due to a disease-state competes with the specific energy needs for growth (Bauer et al, 
2011). In the pediatric population objective anthropometric parameters such as history of weight 
loss and a greater than 5% weight loss in one month is considered abnormal in children (Bunting 
et al, 2013 and Bauer et al, 2011). 
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2.7.1.2. Length / Height: recumbent length is measured for infants and toddlers up to 24 months 
of age and after 24 months of age standing height or stature is measured. Length or height is an 
indicator of a child`s linear growth relative to age and is used to define the shortness or tallness 
of a child. When plotted on a growth chart, the length or height-for-age of a child indicates the 
child`s length/height in comparison to other children of the same age and gender and reflects the 
long-term nutritional status; as length/height is affected more slowly than weight when a child 
experiences undernutrition or overnutrition. Undernutrition may cause poor linear growth or 
stunting which results in the child`s height being less than his/her genetic potential and over 
nutrition may result in early maturation and accelerated linear growth, resulting in a child being 
tall for age. A gain in height/ stature is said to occur more slowly than a gain in weight and may 
therefore require an extended period of nutritional rehabilitation to achieve. In children 1-3 years 
old, the Waterlow criteria can be used to assess the extent of chronic malnutrition resulting in 
stunting (Pediatric Nutrition Reference Guide, 2013).    
 2.7.1.3. Head circumference: Head circumference is an indicator of brain growth and may be 
affected by chronic undernutrition during the critical period of brain development which occurs 
from birth to 36 months of age (Bauer et al, 2011). There is a poor relationship between head 
circumference and nutrition after the age of 36 months. Head size is also affected by genetics and 
in clinical practice a head circumference for age less than the 5
th
 percentile on the head 
circumference for age growth chart is often described as microcephaly and similarly, a head 
circumference- for-age greater than the 95
th
 percentile is described as macrocephaly.   
2.7.1.4. Body mass index in children (BMI): is a screening tool which is age and gender specific 
and is used to identify children who are under or overweight (Pediatric Nutrition Reference 
Guide, 2013). BMI is calculated by using the following equations: 
 
The BMI is also described in the literature as the simplest, most non–invasive and acceptable 
tool that is used to indirectly measure body fatness which can be related to adiposity and health 
risks in children in later life (Bauer et al, 2011). 
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2.7.1.5. Growth charts 
Growth charts are tools consisting of a series of percentile and z-score curves, used to evaluate 
the growth of children by recording a series of anthropometric measurements based on the age 
and gender of the child. Percentiles and z-scores are described as a numeric summary of each 
child`s placement relative to an appropriate reference population on a growth chart, to provide 
the most accurate measure of protein energy malnutrition (Collins et al, 2010). The most 
common growth charts in use today are:  
2.7.1.5.1. The growth charts published by the Centers of Disease Control and Prevention 
(CDC) 
These growth charts are based on pooled data from five National Health and Nutrition 
Examination surveys. 
2.7.1.5.2. The World Health Organization growth charts  
These growth charts are based exclusively on healthy children living under optimal conditions 
for achieving their full growth potential as all the children were breastfed in many different 
countries (Brazil, Ghana, India, Norway, Oman and the United States) and none of the mothers 
used tobacco/cigarettes (WHO, 2010).    
Weight-for-age when plotted on an appropriate growth chart is an indicator of a child`s weight 
compared with other children of the same age and sex and is the most useful tool to track weight 
gain in children. However it is not used to classify a child as underweight or overweight 
(Pediatric Nutrition Reference Guide, 2013). 
Length/height-for-age when plotted on an appropriate growth chart is an indicator of a child`s 
length/height weight compared with other children of the same age and sex and is a useful tool to 
measure the linear growth of a child. It also represents the long term nutritional status of a child 
and is affected more slowly than weight when a child experiences under or over nutrition. 
Undernutrition usually causes poor linear growth or stunting (Pediatric Nutrition Reference 
Guide, 2013). 
Weight- for-length/height is used as an indicator for normal weight or underweight and 
overweight as the body weight is dependent on a child`s stature. A weight-for-length/height 
value below the 5
th
 percentile is indicative of undernutrition and a weight for length/height value 
above the 95
th
 percentile is indicative of over nutrition. 
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BMI- for-age is the most reliable method of predicting a visual assessment of underweight or 
over weight in a child. However children that are athletic may have a BMI value indicative of 
overweight though they lack adiposity. A BMI-for-age less than the 5
th
 percentile are indicative 
of underweight.  
Percentiles and z-scores are used to assess the anthropometric measurements of infants and 
children in order to evaluate their growth and nutritional status (WHO, 2008). Z-scores are said 
to have a number of advantages compared to percentiles in that they are calculated based on the 
distribution of the reference population; reflect the reference distribution and are compared 
across ages, sexes and anthropometric measurements (WHO, 2008). Z-scores can also be 
analyzed as a continuous variable in studies and can therefore be used to quantify the extreme 
growth status at both ends of a distribution (WHO, 2008).  
Table 1 below summarizes recommendations for defining malnutrition based on z-scores. 
Table 1: Recommendations for defining malnutrition based on z-scores (Academy of 
Nutrition and Dietetics, 2015) 
Primary Indicator Mild Malnutrition Moderate Malnutrition 
 
 
Severe Malnutrition 
 
 
 
Weight-for-length z- score 
 
−1 to −1.9 z-score −2 to −2.9  z-score −3 or greater z-score 
 
Length z- score 
 
no data no data −3 or greater z-score 
 
Deceleration in 
weight-for-length z-score 
 
decline of 1  z-score decline of 2  z-scores decline of 3 z-scores 
 
2.7.2. Biochemical and hematology data:  
Laboratory measurements that are most frequently used to assess the nutritional status of 
children include visceral proteins (prealbumin, transferrin and retinol binding protein); blood 
glucose levels; hemoglobin; hematocrit; lymphocyte count; lipid profiles (Madrono et al, 2011).  
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2.7.2.1. Albumin 
Albumin has been widely used as a marker of nutritional status however due to its long half-life 
of 21 days and its ability to be affected by certain medications such as corticosteroids, insulin 
and thyroid hormones; dehydration and certain disease states such as severe liver and renal 
disease, intravascular volume overload, malabsorption syndromes, chemotherapy and zinc 
deficiency, limits its use as a marker for malnutrition (Madrono et al, 2011). Studies have shown 
hypoalbuminemia to be a marker for both malnutrition and severe inflammation. During trauma 
inflammatory mediators’ decrease albumin concentrations thereby facilitating the need for C-
reactive protein levels to be monitored in order to differentiate between the nutritional and 
inflammatory causes of low serum albumin levels (Nieuwoudt, 2011).  
2.7.2.2. Prealbumin 
Prealbumin has a shorter half-life than albumin. Literature by Mosby et al (2009) identifies 
serum prealbumin and retinol binding protein as better indicators of current protein intake and 
nutritional status in children (Mosby et al, 2009). 
2.7.2.3. Blood glucose levels 
In malnourished patients with cancer, glucose intolerance and insulin resistance is common 
occurrence as the result of an increase in glucose production during the fasting state (Dare et al, 
2013). 
2.7.2.4. Hemoglobin 
Hemoglobin carries oxygen and gives blood cells their red color. Hemoglobin levels therefore 
measure the blood`s ability to carry oxygen. Low serum hemoglobin and hematocrit levels are 
common in children receiving chemotherapy and can also be falsely high in patients who are 
dehydrated (Madrono et al, 2011).   
2.7.2.5. Hematocrit 
This test measures the amount of space (volume) red cells occupy in the blood. The value is 
usually expressed as a percentage for example a hematocrit level of 25 means that 25% of the 
bloods volume is made up of red blood cells (Madrono et al, 2011). 
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2.7.2.6. White blood cell count 
Children with ALL are found to have an abundance of immature white blood cells and a small 
number of red blood cells and platelets. The white blood cell count may be found to be normal, 
low or high however more often than not patients with ALL are found to present with 
neutropenia. The severity and prevalence of infections are inversely correlated with the absolute 
neutrophil count. Infections commonly occur when the neutrophil counts are low (Madrono et al, 
2011).    
2.7.2.7. Total lymphocyte count 
Total lymphocyte count is a useful indicator for nutritional status and is appropriate for all age 
groups. Under nutrition causes immunologic changes such as a low total lymphocyte count 
which can increase the frequency and severity of an infection (Madrono et al, 2011).   
2.7.2.8. Platelets (thrombocyte)  
Platelets are the smallest type of blood cell and are important in blood clotting. During injury, 
platelets clump together to stop the bleeding at the site of injury (Madrono et al, 2011).  
2.7.3. Clinical assessment  
Clinical assessment involves the clinical examination of a patient in order to find signs and 
symptoms of nutrient deficiencies or excesses which include the absence or presence of oedema, 
cachexia, obesity, skin changes, dry mucous membranes, petechiae or ecchymoses, healing of 
wounds, glossitis, stomatitis and cheilosis and the evaluation of body composition- including fat 
and muscle stores (Mosby et al, 2009). Other signs of malnutrition are liver enlargement, 
changes in skin, hair, eyes, face, lymph glands, mouth, gums and teeth.  
Table 2 below describes the signs and possible causes of a nutrition –based clinical assessment in 
children. 
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Table 2: Nutrition- focused clinical assessment in children (Pediatric Nutrition Reference 
Guide, 2013). 
Signs  Possible nutrition related causes 
Cachexia  
 
Insufficient protein and energy 
Cheilosis  
 
Insufficient riboflavin 
Delayed wound healing Insufficient vitamin C and zinc. 
Dry mucus membranes Inadequate nutrition.  
Poor fat and muscle stores 
 
Prolonged effect of insufficient energy  
Glossitis Insufficient vitamin B12 
Oedema Insufficient protein. 
Pallor Insufficient iron, vitamin B12, vitamin C, folic acid 
pyridoxine. 
Petechiae or ecchymoses Insufficient vitamin C. 
Stomatitis Insufficient vitamin C. 
Skin changes -Hyperpigmentation  
 
Insufficient vitamin B12, folic acid and niacin. 
 
2.7.4. Diet history 
Diet history plays an important role in the pediatric nutrition assessment of a child as it evaluates 
the usual intake of the child in order to assess the nutritional adequacy of the child`s diet, eating 
and feeding behaviors and food consumption patterns. Information included in the diet history 
should include the following (Mosby et al, 2009): 
a. Home feeding regimes 
b. Food preferences – types, textures 
c. Food allergies and food intolerances 
d. Feeding environment 
e. Problems when chewing or swallowing 
f. Religious and cultural food habits 
g. The use of vitamin and mineral supplements 
h. Feeding skills of the child based on the child`s age 
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i. Stooling habits  
j. Developmental level and sleep patterns  
There are several methods in practice today for obtaining the diet history of a child and the most 
frequently used methods are the 24 hour recall; 3-Day food record; food frequency and calorie 
count. Regardless of the method used, the diet history should provide all the necessary 
information required to estimate the macronutrient and micronutrient content of the child’s diet 
(Mosby et al, 2009).   
Malnutrition is a condition that encompasses both states of a deficiency (undernutrition) and / or 
an excess in energy, protein and other nutrients (over-nutrition/ obesity) (Joosten et al, 2011). 
Primary undernutrition which occurs as a result of an inadequate food intake is common in 
children from lower socioeconomic countries and is often present at the time of ALL diagnosis 
(Mosby et al, 2009). Secondary undernutrition, on the other hand, occurs as a result of `the 
disease state ` and is frequently observed in children undergoing cancer therapy which occurs as 
a result of treatment-related complications such as a mucositis, anorexia, nausea, vomiting and 
malabsorption (Mosby et al, 2009). 
In developing countries, socioeconomic and nutritional factors play a role in the prognostic 
evaluation of children with ALL (Khan et al, 2006). Malnutrition is also more visible at 
diagnosis as a result of low energy intakes versus an increased energy demand whereas in 
developed countries children with ALL were found to show a lower prevalence of malnutrition at 
diagnosis. Clinical trials have also shown that undernutrition is an adverse prognostic factor in 
children with ALL as it decreases bone marrow reserves, leading to frequent relapses and a 
shortened remission phase (Khan et al, 2006). A study by Khan et al (2006) conducted on 163 
pediatric patients diagnosed with ALL, of whom 102 were undernourished and 61 well 
nourished, reported that underweight children were less likely to complete their treatment and 
were therefore at a higher risk for relapses and mortality than children who were of normal 
weight at diagnosis.  
Malnutrition and cancer cachexia are frequent consequences of pediatric cancer and its 
treatment. Cachexia also known as wasting syndrome is said to alter the body’s compensatory 
mechanisms to conserve protein and decrease energy expenditure (Ladas et al, 2005). Cancer 
cachexia, though not fully understood, is characterized by wasting of lean muscle tissue, muscle 
atrophy, fatigue and weight loss due to early satiety (Ladas et al, 2005). Studies have shown that 
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cytokines are involved in the alteration of protein, carbohydrate and lipid metabolism which 
results in loss of lean muscle tissue and muscle atrophy (Nieuwoudt, 2011; Ladas et al, 2005).   
2.8. Side-effects of cancer treatment 
`Pediatric cancer survivors are reported to be twice as likely to be diagnosed with hypertension, 
dyslipidemia, and type 2 diabetes and up to seven times more likely to experience cardiac 
conditions than their siblings in later life` (Rosen et al, 2013). 
2.8.1. Overweight and obesity 
Glucocorticoid therapy which forms part of the treatment protocol for ALL in children has a side 
effect of causing excessive weight gain which can lead to obesity. This is a common feature in 
children during and after treatment (Murphy et al, 2006). Steroids are known to initiate negative 
anabolic effects like an increased appetite causing an increased energy intake, accompanied by 
altered substrate oxidation and fat accumulation around the areas of the neck, face, waistline and 
arm circumference (Tan et al, 2013). Dexamethasone and prednisolone are two glucocorticoids 
that are used to treat ALL. Several studies claim dexamethasone to be more beneficial in the 
treatment of ALL in children; however it was also found to be more toxic than prednisolone, 
causing greater fat mass and weight gain in patients (Murphy et al, 2006). `Dexamethasone is 
reported to be 18 times as potent as prednisolone in suppressing short term growth and in 
increasing body weight`(Murphy et al, 2006 citing Ahmed et al, 2002) and `patients on 
dexamethasone were reported to gain significantly more weight than patients treated with an 
equivalent dose of prednisolone` (Murphy et al, 2006 citing Groot-Loonen et al, 1996). A study 
by Collins et al (2010) found children on ALL treatments with dexamethasone to have a greater 
prevalence of overweight/ obesity post induction remission. It was also observed that the most 
weight gain occurred during the delayed intensification phase; when glucocorticoids were used 
for a longer period of time as compared with other treatment phases (Tan et al, 2013 and 
Lughetti et al, 2012). In the national health survey study conducted in Italy by Lughetti et al 
(2012) which included 414 ALL survivors, body weight was found to significantly increase 
during the first year post treatment and was found to continue for 4 years post follow up in ALL 
survivors. Underweight and overweight are considered undesirable for children diagnosed with 
leukemia as it is an indicator of poor prognosis (Tan et al, 2013).   
A study by Baillargeon et al (2005) reported the weight gain pattern in Hispanic children with 
ALL who had normal BMI at diagnosis to have a significant increase in BMI between the start of 
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treatment and 12 months after treatment; a moderate increase in BMI was seen between 12 to 24 
months after treatment initiation and slight decrease in BMI was observed 30 months after 
initiation of treatment. In the same study children who were found to be overweight at diagnosis, 
over time showed no significant increase or decrease in BMI and girls were found to become 
obese between diagnosis and at the end of treatment whereas boys were found to have a gradual 
increase in BMI until adolescence (Baillargeon et al, 2005).  
Past studies have suggested that the increased adiposity observed in children on ALL treatment 
could be linked to a decrease in growth hormone and resistance to leptin. Leptin is an adipocyte-
derived hormone which normally regulates appetite and energy expenditure, however when fat 
mass increases (as in the case of an increased caloric intake) leptin levels were found to increase 
as well, resulting in leptin resistance which gives rise to obesity (Tan et al, 2013).  Research by 
Arguelles and colleagues cited by Lughetti et al (2012) found a positive correlation between 
weights, BMI and skinfold measurements and serum leptin levels in children 36 months post 
ALL diagnosis. `Serum leptin levels were reported to be elevated 6 months post ALL diagnosis 
and one year after chemotherapy withdrawal` (Lughetti et al, 2012). Obesity and overweight are 
also implicated in the development of other co-morbid conditions such as type 2 diabetes, 
metabolic syndrome, lipid abnormalities, hypertension, cardiovascular disease and secondary 
cancers (Hunger et al, 2015). Recent research by Zhang et al (2014)  conducted on 1742 
pediatric ALL survivors found the BMI z-score for these subjects to be considerably higher than 
that of the standard reference population with the strongest risk for obesity occurring in pediatric 
ALL survivors who were off treatment for less than 5 years.      
The Middle Eastern study by Al-Mulla et al (2014) on 1150 ALL subjects found 87.4 % of the 
subjects to have a normal nutritional status based on the weight for age of subjects at diagnosis 
and only 3.1% of subjects were found to be obese. 
2.8.2. Lifestyle changes 
Hospitalization to start chemotherapy; combined with impaired motor function and reduced 
physical activity has been linked to the high incidence of overweight and obesity in children 
receiving treatment for ALL (Zalina et al, 2009). Glucocorticoid treatment was found to reduce 
muscle mass and cause motor neuropathies that could persist for up to 2 years after treatment 
(Rosen et al, 2013).  
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2.8.3. Changes in taste 
Cancer treatments such as chemotherapy and bone marrow transplantation is said to cause 
changes in taste perception (increased sourness and bitterness or a metallic taste) in children on  
treatment, this can negatively impact on the nutritional status of child therefore the assessment of 
energy intake is a key part of the nutritional assessment. Growth in children is said to occur as a 
result of a sustained increase in lean body mass and fat combined with an inadequate intake of 
nutrients during childhood years (Ladas et al, 2005).  
2.8.4. Vomiting and nausea 
The prolonged effects of chemotherapy often induces vomiting which has a damaging effect on 
the gastrointestinal tract, causing lesions and inflammation to the epithelial lining of the gut. This 
in turn decreases food intake and absorption. Chemotherapy -induced nausea, diarrhea and taste 
changes further decrease food intake especially during the induction and consolidation phase of 
treatment (Skolin et al, 2006).  
2.8.5. Other gastrointestinal complications of cancer therapy 
These include diarrhea, constipation, and mucositis and reduced gastrointestinal motility. 
Diarrhea was found to influence a child`s dietary intake and absorption of nutrients which may 
lead to dehydration and electrolyte imbalances if untreated (Ladas et al, 2005). Constipation has 
been frequently observed in children with cancer receiving vincristine containing regimens 
(Ladas et al, 2005). A significant number of children on cancer treatment develop mucositis 
which results in lesions (increased risk for systemic infections), pain and oral hemorrhage which 
reduces their oral intake and increases their risk for under-nutrition (Owens et al, 2011). Most 
studies have found ALL patients with Downs syndrome to have more reports of mucositis during 
treatment than non-Downs syndrome patients (Maloney, 2011). Chemotherapy and the use of 
broad spectrum antibiotics in ALL patients has been reported to directly impact on the structure 
of the microbiota in the gut which directly affects nutrient availability and absorption and 
indirectly affects carbohydrate digestion and fermentation resulting in increased calorie 
absorption, obesity and insulin resistance (Rosen et al, 2013).  
2.8.6. Hyperglycemia 
Hyperglycemia has been identified as a complication during induction therapy in children. The 
use of high dose steroids, L-asparaginase, intravenous fluids and diet has been suggested to 
contribute to the prevalence of hyperglycemia during induction phase chemotherapy (Dane et al, 
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2013). Glucocorticoids can increase blood glucose by blocking the effects of insulin by 
increasing liver gluconeogenesis; L-asparaginase on the other hand decreases insulin levels. 
Literature by Dane et al (2013) has also suggested that `increased exposure to dexamethasone 
independently increases glucose and immune paresis with a resultant increase in infection rates`. 
Patients with Downs syndrome were found to have a higher incidence of treatment-related 
hyperglycemia during induction chemotherapy; although the reason is unclear it has been 
suggested that an increased tendency to islet cell autoimmunity or the reduced functioning of 
pancreatic reserve may be a possible cause (Dare et al, 2013). Chemotherapeutic agents such as 
methotrexate and doxorubicin have been found to alter the gut barrier which triggers the release 
of lipopolysaccharides produced by the gram negative bacteria in the intestine and this in turn 
causes metabolic endotoxemia which induces insulin resistance (Rosen et al, 2013).  
2.8.7. Osteoporosis  
Bone mass is often reduced at diagnosis of ALL and falls dramatically during the first 6 months 
of chemotherapy (Salim et al, 2013). The long term use of corticosteroids and antiemetics reduce 
the synthesis of collagen causing easy bruising, decreased absorption and bone loss giving rise to 
osteomalacia, osteoporosis and skeletal anomalies in children receiving treatment for ALL 
(Rosen et al, 2013). Literature by Salim et al (2014) noted that osteopenia and osteoporosis was 
observed during all phases of ALL treatment and throughout the post treatment period for up to 
20 years. In total 39% of children with ALL had fractures by completion of their treatment. The 
fracture rate in children with ALL was found to be 6 times more than in healthy children up to 12 
months following chemotherapy (Salim et al, 2014 citing Rogalsky et al, 1986).   
2.9. Nutrition support in pediatric cancer 
Studies report approximately 46 % of children with cancer experience malnutrition as a result of 
the disease and of complications that may arise as a result of chemotherapy such as xerostomia; 
mucositis; food aversion resulting from vomiting; and nephrotoxicity which causes increased 
nutrient losses (Bauer et al, 2011; Owen et al, 2013). Steroids induce hyperglycemia, fluid 
retention, weight gain, altered body composition, electrolyte and imbalances and increase the 
long term requirements for calcium, zinc, vitamin C and vitamin D in children on ALL treatment 
(Owens et al, 2013).  
Early identification of undernourished patients from diagnosis and throughout the lengthy 
treatment process is essential to ensure patients receive their recommended caloric intake based 
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on their current condition and age, in spite of the negative effects of intense cycles of 
chemotherapy (Bauer et al, 2011). Nutritional support in childhood cancer is therefore aimed at 
preventing or reversing the effects of protein energy malnutrition to sustain and promote normal 
growth; enhancing therapy; decreasing the complications of cancer treatment; improving the 
immune status of the child; treating nutritional deficiencies and promoting normal eating 
behavior in order to improve the quality of life (Selwood et al, 2010; Gonzalez et al, 2004). 
Table 3 below describes the short term and long term consequences of malnutrition on pediatric 
cancer patients (Bauer et al, 2011).    
Table 3: Short term and long term consequences of malnutrition on pediatric cancer 
patients (Bauer et al, 2011). 
SHORT TERM CONSEQUENCES LONG TERM CONSEQUENCES 
 Wasting of muscle and fat mass. 
 Decreased tolerance of chemotherapy. 
 Unfavorable response to 
chemotherapy. 
 Treatment delays. 
 Fatigue. 
 Biochemical disturbances (anemia, 
hypoalbuminemia). 
 Delayed recovery of normal bone 
marrow. 
 Changes in body composition. 
 Drug dose alterations 
 Decreased quality of life. 
 Greater levels of psychological 
distress. 
 Higher susceptibility to infections. 
 Growth impairment resulting in 
reduced final height. 
 Impact on motor, cognitive and 
neurodevelopmental impairment. 
 Risk for metabolic syndrome. 
 Risk for secondary cancers. 
 Risk for aging. 
 Increased mortality rate. 
 Retardation of skeletal maturation. 
 Abnormal bone mineral density. 
 Decreased quality of life. 
 
Currently there is a lack of internationally specific nutrition guidelines for pediatric cancer 
patients. This makes nutritional support a challenge as cancer treatments affect a child`s appetite, 
tolerance to food and fluids and utilization of food to promote and maintain normal growth. 
Several tools have been identified to estimate the energy and nutrient needs of a child with 
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cancer which includes age-appropriate Dietary Reference Intakes (DRI) and The World Health 
Organization`s equations for basal metabolic rate. Literature by Nieuwoudt (2011) quotes The 
Children`s Oncology Committee recommendation to increase the calorie needs for a child 
undergoing cancer treatment by approximately 20% above their normal requirements and to 
increase their protein needs by 50% above their normal requirements. 
Nutrition support guidelines by Bauer et al (2011) to treat undernutrition recommends the 
following:   
2.9.1. Oral feeding 
Oral feeding is recommended as the first route of feeding, especially for children with low 
nutrition risk who are able to consume sufficient nutrients. Dietary counselling with the input of 
a registered dietitian is important to enhance the oral intake of the child and an individualized 
approach with family participation is vital to enable families to overcome the side-effects of 
cancer treatment (a loss of appetite, nausea, vomiting, mucositis and stomatitis) which negatively 
impact a child`s oral intake. The majority of children was found to require a balanced age-
appropriate diet with food fortification to make foods and snacks more energy dense with or 
without the addition of high calorie oral nutritional supplements and nutrition education on 
eating problems related to the side-effects of treatment. In a hospital setting procedure and 
treatment timings were found to interfere with mealtimes. Patients were also admitted for long 
periods of time which made meals repetitive and boring. One study addressed this problem by 
providing a cook to order service with individualized age- appropriate portion sizes, child-
friendly cutlery and crockery and the provision of snacks throughout the day for children who 
cannot tolerate full meals (Bauer et al, 2011). 
Children undergoing chemotherapy often experience taste and smell changes. These 
chemosensory changes can affect the perceived flavor of oral nutritional supplements frequently 
prescribed. Research regarding the palatability of oral nutritional supplements in pediatric cancer 
patients undergoing chemotherapy is lacking. A study by Ijpma et al (2016) conducted on 60 
adult patients with gastric cancer found the palatability of milk-based vanilla oral nutritional 
supplement to decrease over time, namely before, during and after chemotherapy; however the 
palatability of a milk based strawberry oral nutritional supplement was preferred before, during 
and after chemotherapy. It was therefore the recommendation of this study to offer a variety of 
types and flavors to malnourished cancer patients throughout the treatment period.     
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2.9.2. Enteral feeding 
Enteral nutrition by means of a nasogastric tube feed (NGT) or percutaneous endoscopic 
gastrostomy (PEG) or jejunostomy has been shown to be successful in reversing malnutrition 
and maintaining an adequate nutritional status in children with a `high risk for malnutrition` and  
a poor oral intake and who are unable to meet their nutritional needs via the oral route 
(Nieuwoudt, 2011). Enteral nutrition as a sole source of nutrition or as an overnight enteral feed 
has been found to be safe and effective in the home environment for pediatric cancer patients 
who are unable to consume an adequate oral diet. It has a lower risk for infection, preserves gut 
integrity and reduces bacterial translocation and is thus recommended since it is more practical 
and safer than parenteral nutrition (Bauer et al, 2011 citing Rickard et al, 1986). 
Multiple studies have reported success in improving the nutritional status of children by means 
of nasogastric tube feeds, during intensive cancer treatments including bone marrow 
transplantation with minimal complications (Selwood et al, 2011 citing De Swarte-Wallace et al, 
2001; Pietsch et al, 2000; den Broeder et al, 1998). Enteral formulas containing intact protein 
were found to be well tolerated during chemotherapy cycles however following chemotherapy 
protein hydrolysate and amino acid based formulas were found to be better tolerated as children 
may display reduced gastrointestinal motility with a risk for malabsorption (Selwood et al, 2011 
citing Ward, 2003).  
The recommended criteria for starting enteral feeding according to Bauer et al (2011) are: 
 Weight two centiles below height centile.  
 Percentage weight for height < 90% of the ideal. 
 Decrease in current percentiles for weight or height of two centiles. 
 Total weight loss > 5% since diagnosis. 
 Reduced oral intake of < 70% of estimated average requirement for > 5 days. 
Nasogastric and nasoduodenal feeding is recommended for short duration feeding as these 
feeding devices cause nasal discomfort, recurrent pulmonary aspiration and easy tube 
dislodgment (El- Matary, 2008). For long duration feeding gastrostomy (a tube is inserted 
directly into the   stomach through an opening in the anterior abdominal wall) or jejunostomy (a 
tube is inserted directly into the small intestine) feeding tubes are recommended. Enteral 
nutrition is however discouraged in cancer patients with mucositis and enteral tube insertion is 
not recommended in children with neutropenia or thrombocytopenia as these children have an 
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increased risk of bleeding during feeding tube insertion (El- Matary, 2008). A study conducted 
by Barbosa et al (2012) found malnourished children with cancer to show improved growth 
parameters, in terms of z-scores for weight-for-age and BMI, during the administration of enteral 
nutrition. The side-effects of cancer treatments such as nausea, vomiting and diarrhea pose 
limitations to the use of enteral nutrition support in cancer patients. The addition of prokinetic 
agents and post pyloric feeding has been found to minimize vomiting (Barbosa et al, 2012).  A 
multidisciplinary team is important to ensure adequate nutritional support for children and adults 
with cancer. 
2.9.3. Total parenteral nutrition 
Total parenteral nutrition (TPN) is recommended for patients whose enteral feeding regimes are 
unable to provide adequate nutrients. Parenteral nutrition is used primarily for nutrition support 
when the gastrointestinal tract cannot be used. The general consensus from a number of studies 
conclude that parenteral nutrition should be reserved for children who are unable to tolerate 
enteral feeding as a result of an abnormal gastrointestinal function either related to the treatment 
or the tumor. In pediatric cancer patients it is mainly used for those with severe mucositis or 
neutropenic colitis (Nieuwoudt, 2011; Ladas et al, 2005). 
The choice of central versus peripheral parenteral nutrition depends on the length of therapy. 
Peripheral parenteral nutrition is recommended for short term therapy which usually lasts 
between 7 to 10 days. Parenteral nutrition therapy requires more monitoring than enteral 
nutrition and carries the highest incidence of septic complications (Nieuwoudt, 2011). Most 
studies aiming to assess the effectiveness of TPN in pediatric cancer patients have found a 
positive effect on reversing malnutrition during the initial phase of treatment (Andrassy et al, 
1998; Rickard et al, 1986; Donaldson et al, 1982). TPN is associated with liver disease which 
remains a dreaded complication of parenteral nutrition in children. The risk of refeeding 
syndrome remains a serious complication in aggressive nutritional rehabilitation (by enteral and / 
or parenteral route) in severely malnourished children with cancer (Nieuwoudt, 2011). Literature 
by Nieuwoudt (2011) report that  `a recent Cochrane Review (to determine the effects of enteral 
and parenteral support in children with cancer undergoing chemotherapy) found limited evidence 
to suggest that parenteral nutrition is more effective than enteral nutrition in well-nourished 
children and young people with cancer undergoing chemotherapy`.  Clinical studies reported by 
Andrassy et al (1998) found well-nourished children receiving `abdominal radiation and 
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intensive chemotherapy to demonstrate improved maintenance of body weight, fat and muscle 
reserves when administered TPN in contrast to those on oral diets`. 
2.9.4. Vitamin and mineral supplements 
Some authors suggest that vitamin and mineral supplements are needed to compensate for the 
reduction in antioxidants which occurs as a result of chemotherapy. It has been suggested that the 
use of antioxidants during chemotherapy could interfere with the action of chemotherapeutic 
drugs on the tumor and thereby reduce the efficacy of the treatment (Rickard et al, 1986). 
Therefore the use of antioxidants in cancer treatment regimens remains controversial as studies 
so far have been inadequate and inconsistent to guide clinical practice (Nieuwoudt, 2011).  
The use of multivitamin and mineral supplement is recommended in the case of poor oral intake 
in children with cancer, however children who are eating a variety of foods in their diet will not 
benefit from such a supplement. Vitamins when given in excess cause toxicity therefore 
administration of mega doses of a single vitamin are not encouraged. Children receiving 
nutritionally complete sip feeds and those on a enteral feeding regimes will not require additional 
vitamins as their requirements will be met by the sip feed / formula (Nieuwoudt, 2011).  
2.9.5. Glutamine supplementation 
`Glutamine supplementation has been recommended in the relief of severe mucositis however 
more research in this area is needed` (Nieuwoudt, 2011). There has also been inconsistent or 
unconfirmed evidence regarding the use of pre and probiotics in the nutritional management of 
pediatric cancer patients and the American Academy of Pediatrics has recommend that the use of 
pre and probiotics be avoided in seriously or chronically ill children until the safety of 
administration has been established (Nieuwoudt, 2011). 
2.10. Summary  
The literature suggests that approximately 46 % of children with cancer experience malnutrition 
as a result of the disease and the complications that may arise as a result of chemotherapy such as 
xerostomia; mucositis; food aversion resulting from vomiting; and nephrotoxicity which causes 
increased nutrient losses. Therefore early identification of undernourished patients from 
diagnosis and throughout the lengthy treatment process is essential to ensure patients receive 
their recommended caloric intake based on their current condition and age, in spite of the 
negative effects of intense cycles of chemotherapy. Currently there is a lack to internationally 
specific nutrition guidelines for pediatric cancer patients. This makes nutritional support a 
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challenge as cancer treatments affect a child`s appetite, tolerance to food and fluids and 
utilization of food to promote and maintain normal growth. 
Oral feeding is recommended as the first route of feeding, especially for children with low 
nutrition risk who are able to consume sufficient nutrients. Dietary counselling with the input of 
a registered dietitian is important to enhance the oral intake of the child and an individualized 
approach with family participation is vital to enable families to overcome the side-effects of 
cancer treatment (a loss of appetite, nausea, vomiting, mucositis and stomatitis) which negatively 
impact a child`s oral intake. 
Enteral nutrition by means of a nasogastric tube feed (NGT), percutaneous endoscopic 
gastrostomy (PEG), jejunostomy has been shown to be successful in reversing malnutrition and 
maintaining an adequate nutritional status in children with a `high risk for malnutrition `, poor 
oral intake and who are unable to meet their nutritional needs via the oral route 
The general consensus from a number of studies suggest that parenteral nutrition should be 
reserved for children who are unable to tolerate enteral feeding as a result of an abnormal 
gastrointestinal function either related to the treatment or the tumor. In pediatric cancer patients 
it is mainly used for those with severe mucositis or neutropenic colitis. 
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METHODOLOGY  
The study design, study sample, methods used to collate and analyze the data to achieve the aims 
and objectives of the study is presented in this chapter. 
3.1. Study design 
A retrospective descriptive case study design was used.  
3.2. Study population and study sample  
The study population consisted of electronic medical records of patients aged between 1-14 years 
who was newly diagnosed with Acute Lymphoblastic Leukemia (ALL) and admitted to Sheikh 
Khalifa Medical City for treatment during the period 1 January 2012 and 31 Dec 2014. The study 
sample consisted of 20 electronic medical records of patients who were admitted and completed 
all phases of treatment (induction, consolidation, delayed intensification and maintenance) at 
Sheikh Khalifa Medical City during this time frame (1 January 2012 and 31 Dec 2014).   
Inclusion criteria: 
All pediatric patients between the ages of 1-14 years old newly diagnosed with acute 
lymphoblastic leukemia (ALL) and received all phases of chemotherapy treatment at Sheikh 
Khalifa Medical City, between 1 January 2012 to 31 December 2014.   
Exclusion Criteria: 
All pediatric patients below the age of 1 year old or above the age of 14 years old newly 
diagnosed with acute lymphoblastic leukemia (ALL) and received treatment at Sheikh Khalifa 
Medical City, between 1 January 2012 to 31 December 2014. 
All pediatric patients  between the ages of 1-14 years old newly diagnosed with acute 
lymphoblastic leukemia (ALL) and who failed to complete all stages of treatment at Sheikh 
Khalifa Medical City, between 1 January 2012 to 31 December 2014.   
3.3. Data collection method  
Identification of suitable participants began through a review of each potential study participant`s 
electronic medical record.  
Data was collected and recorded on a data collection form (Appendix III) from the electronic 
medical record for each suitable participant for the following at admission and during the full 
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duration of all phases of cancer treatment namely induction, consolidation, interim maintenance, 
delayed intensification and maintenance: 
 Age  
 Gender 
 Date of diagnosis (dd/mm/yyyy) 
 Symptoms on diagnosis 
 Cancer diagnosis (type, subtype, new diagnosis). 
 Anthropometric measurements (weight, length/ height, head circumference). 
 Biochemical values (visceral proteins, blood glucose levels, hemoglobin, hematocrit, 
lymphocyte count). 
 Clinical assessment (stomatitis, anemia, mucositis). 
 Diet history (home feeding regimes; consumption of daily requirements; food 
preferences – types, textures; food allergies, food intolerances; food aversions; use of 
oral nutritional supplements; treatment-related side-effects). 
 Systemic related side-effects (nausea; vomiting; diarrhea; anorexia; appetite changes; 
taste changes; physical activity level; depression).  
 Dietary requirements (age and gender related nutritional requirements for energy, 
protein, fat and fluids). 
 Indications for nutritional support (oral feeding; enteral feeding; parenteral feeding).  
Anthropometry: 
Patient`s weight and length/height measurements were recorded at diagnosis and at the start and 
end of each treatment phase from the patient`s electronic medical record. Patient weights were 
recorded in kilograms (kg) with a precision of 0.1kg using a SECA digital scale. The weighing 
scales on the hospital wards are calibrated monthly as per hospital policy. Young children below 
the age of 24 months old were weighed unclothed and older children above the age of 24 months 
old were weighed with clothes (no shoes) and weight was thereafter adjusted for clothes. The 
length/ height was measured in centimeters; young children (below 24 months old) were 
measured in the recumbent position and older children (24 months and older) were measured 
standing up. The head circumference of children (12 – 36 months old) was measured in 
centimeters, using a tape measure around the largest part of the head. The body mass index 
(BMI) was calculated with the most current weight and height measurements using the following 
formula:  
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The anthropometric measurements which were included in the electronic medical record of each 
patient included in the study were electronically plotted on the World Health Organization 
growth charts according to the age and gender of each patient. 
Biochemical indices of nutritional status 
Biochemical/ laboratory values namely visceral proteins - total protein (g/L), albumin (g/L); 
blood glucose levels (millimole/L); hemoglobin (g/L); hematocrit (L/L);, lymphocyte count (%); 
white blood cell count was measured at various stages of treatment as per the existing treatment 
protocols for ALL.  
Diet history and Nutritional interventions 
Information on the diet history of patients namely 24 hour dietary recall; food frequency lists; 
home feeding regimes; food preferences to include food likes and dislikes, food textures, feeding 
environment, food allergies, food intolerances, food consumption patterns, dietary requirements, 
treatment-related side-effects and nutritional support interventions were collected from the 
dietitian notes in the patients file.   
3.4. Analysis and interpretation of the data 
The data collected on the data collection form (Appendix IV) was entered into Microsoft Excel 
2010 spreadsheet (Addendum V).  
The weights and length/ heights of participant recorded in the electronic medical records was 
plotted on the World Health Organization growth charts and then converted to z-scores. Z-scores 
are a numerical summary of each child`s placement relative to an appropriate reference 
population (Collins et al, 2010). A significant growth abnormality was evident if a participant`s 
z-score for weight-for-age and/or length/height-for-age and/or weight-for length/height and/or 
BMI-for-age was more than 2 standard deviations greater than or less than the appropriate mean 
(Bauer et al, 2011) or if a participant experienced a weight loss of greater than 5% of body 
weight over a period of one month even though participant was not classified as undernourished 
by anthropometric parameters (Bauer et al, 2011; Jeejeebhoy and Keith, 2005).   
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The biochemical indices of nutritional status were captured from each participant’s electronic 
medical record and compared and interpreted with reference values in context of the age and sex 
of each participant. 
The prescriptions of nutritional interventions were captured from each participant’s electronic 
medical record and compared and interpreted in comparison to the biochemical indices, 
anthropometric status and dietary intake of each participant. 
All the data involving changes in anthropometrics, biochemistry, diet history and nutritional 
interventions, from each case study, from diagnosis and through all stages of treatment 
(induction, consolidation, interim maintenance, delayed intensification and maintenance) was 
screened and compared with reference values in the context of the age and sex of participants 
and evidence based nutritional guidelines; in order to document the outcomes of the medical 
nutrition treatment provided. This was done to determine whether the nutrition interventions 
provided during each treatment phase had an impact on the nutritional status of each case study. 
These results were then used to develop a nutrition support protocol for children with Acute 
Lymphoblastic Leukemia at SKMC in order to reduce the risk of nutrition related problems. This 
protocol will serve to standardize the feeding practices and achieve the nutritional goals of 
children on ALL treatment.   
3.5. Validity and reliability 
It is recognized that the validity and reliability of the data depends on the completeness, 
correctness and accuracy of the recording in the electronic patient medical records.  The data 
recording form was piloted using the electronic patient files of children with Acute Myeloid 
Leukemia (AML). The researcher was the only person entering the data into Excel and double 
entry was done to ensure reliability.  
3.6. LIMITATIONS OF THE STUDY 
The study is limited by the detail, completeness, quality and accuracy of information from 
electronic patient medical files.  
3.7. ETHICAL CONSIDERATIONS 
Ethics approval was obtained from the Sheikh Khalifa Medical City Research Ethics Committee 
in order to assess the patient’s electronic medical files (Appendix I), as well as the University of 
Western Cape Ethics Committee (Appendix II). There was no personal interaction with patients 
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as data was obtained from each patient’s electronic medical record. No separate individual 
patient consent was needed to conduct this research, but all data was treated as confidential and 
code numbers were used instead of patients’ names, also no identifiable data was used in the 
collection of data or in the publication of this study. 
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Results  
The results of the 20 newly diagnosed ALL subjects admitted between 1 January 2012 and 31 
December 2014 to Sheikh Khalifa Medical City (Abu Dhabi, UAE) obtained from the subject`s 
electronic medical record are presented in this chapter. 
4.1. Clinical characteristics at diagnosis 
The most common clinical characteristics reported at diagnosis were fever, purpuric bruises, flu-
like symptoms, anemia, weight loss, bone pain and epistaxis.  
4.2. Demographic profile and type of ALL of the study sample 
The table below describes the demographics of the 20 subjects who participated in this study by 
sex, age group and type of ALL at diagnosis. 
Table 4: The demographics of 20 newly diagnosed ALL subjects by sex, age group and type 
of ALL at diagnosis  
Age in years  No. of males No.  of females  No. of subjects with 
Pre B Cell ALL 
No. of subjects with 
B-cell ALL 
No. of subjects with 
T-cell ALL 
1-2 7 1 2 6 0 
3-4 5 2 2 5 0 
5-6 0 1 1 0 0 
7-8 1 0 0 0 1 
9-10 0 1 0 1 0 
11-12 2 0 1 0 1 
No: number 
There was a male predominance amongst subjects diagnosed with ALL with 15 subjects being 
male (75%) and 5 subjects being female (25%).  
ALL is classified according to the type of lymphocyte (B cell or T cell) the leukemic cells are 
found in and the degree of maturity of the cells (American Cancer Association, 2015). Eighteen 
subjects were diagnosed with B and Pre B cell ALL (90%) and 2 subjects were diagnosed with 
T-cell ALL (10%). 
At diagnosis, risk groups are used to classify ALL instead of stages. In this study 16 subjects 
were diagnosed with standard risk ALL (80%) [Initial white blood cell count less than 50 000] 
and 4 subjects were diagnosed with high risk ALL (20%) [Initial white blood cell count was 
greater than 50 000]. Four subjects (20%) were diagnosed with high risk ALL (all males) with 
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two subjects belonging to the 11-12 year age group and 2 subjects belonging to the 3-4 year age 
group. One subject with high risk ALL had testicular involvement.  
4.3. Anthropometric z-scores and prevalence of malnutrition 
Anthropometric measurements for all subjects at diagnosis and at the start and end of each 
treatment phase were recorded as z-scores for weight-for-age, length/height-for-age and BMI- 
for-age on the World Health Organization (WHO) growth charts. A growth abnormality was 
deemed significant if a subject`s z-score for any of the above mentioned anthropometric 
measurements, was found to be more than 2 standard deviations greater than or less than the 
appropriate mean. Table 4 and table 5 below shows the prevalence of malnutrition at diagnosis 
and at the start and end of each treatment phase.  
Table 5: The prevalence of malnutrition in subjects based on anthropometry (expressed as 
`percentage of subjects`) newly diagnosed with ALL at diagnosis and at the start of each 
treatment phase  
Indicators D 
 
I 
 
C 
 
IM 
 
DI 
 
M 
 
Weight-for-age z-score < -2SD 
(Underweight) 
0 0 0 0 0 5 
Weight-for-age z-score > 2SD 
(Overweight)  
0 0 5 0 0 0 
Weight for height z-score < -2SD 
(Wasting) 
0 0 0 0 5 0 
Weight for height z-score > 2SD 
(Overweight) 
0 0 10 0 0 5 
Height-for-age z-score < -2SD 
(Stunting) 
5 5 10 10 5 5 
Height-for-age z-score > 2SD 
 
0 0 0 5 5 0 
BMI-for-age z-score < -2SD 
(Underweight) 
5 5 0 5 5 0 
BMI-for-age z-score > 2SD 
(Overweight) 
5 10 5 0 0 5 
 
D: Diagnosis, I: Induction treatment, C: Consolidation treatment, IM: Interim Maintenance treatment, DI: Delayed 
Intensification treatment, M: Maintenance treatment, SD: standard deviation.  
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Table 6: The prevalence of malnutrition in subjects based on anthropometry (expressed as 
`percentage of subjects`) newly diagnosed with ALL at the end of each treatment phase  
Indicators I 
 
C 
 
IM 
 
DI 
 
M 
 
Weight-for-age z-score < -2SD 
(Underweight) 
0 0 5 0 0 
Weight-for-age z-score > 2SD 
(Overweight) 
5 0 0 0 0 
Weight for height z-score < -2SD 
(Wasting)  
0 0 5 0 0 
Weight for height z-score > 2SD 
(Overweight) 
10 0 0 0 15 
Height-for-age z-score < -2SD 
(Stunting) 
5 10 10 5 5 
Height-for-age z-score > 2SD 
 
0 0 5 5 10 
BMI-for-age z-score < -2SD 
(Underweight) 
0 0 5 5 0 
BMI-for-age z-score > 2SD 
(Overweight) 
10 0 0 0 10 
 
I: Induction treatment, C: Consolidation treatment, IM: Interim Maintenance treatment, DI: Delayed Intensification 
treatment, M: Maintenance treatment, SD: standard deviation. 
 
4.3.1. Weight-for-age z-scores 
At diagnosis: All subjects (100 %) were found to have normal weight-for-age z-scores.  
Induction treatment: at the start and end of induction treatment all subjects (100%) were found to 
be of normal weight-for-age.  
Consolidation treatment: at the start of consolidation treatment one subject (5%) was found to be 
overweight (this subject was male from the 7-8 year age group and diagnosed with standard risk 
T-cell ALL). At the end of treatment all subjects (100%) including the subject that was 
overweight at the start of treatment were found to be of normal weight-for-age.  
Interim maintenance treatment: at the start of interim maintenance treatment all subjects (100%) 
were found to be of a normal weight-for-age. At the end of treatment one subject (5%) with a 
normal weight at the start of treatment was found to be underweight (this subject was a male 
from the 1-2 year age group and diagnosed with standard risk Pre B cell ALL).  
 
 
 
 
  
44 
Delayed intensification treatment: at the start and end of delayed intensification treatment all 
subjects (100%) were found to be of a normal weight-for-age. The subject that was found be 
underweight at the end of the last treatment phase was able to gain weight as a result of a   
treatment delay (for a low neutrophil count) between treatment phases which lasted 10 days.  
Maintenance treatment: at the start of maintenance treatment one subject (5%) was found to be 
underweight (this subject was a male from the 1-2 year age group and diagnosed with standard 
risk Pre B cell ALL and was also found to be underweight-for-age on completion of interim 
maintenance treatment). At the end of treatment all subjects (100%) were found to be of normal 
weight-for-age.  
4.3.2. Weight- for-height z-scores 
At diagnosis: at diagnosis all subjects (100%) were found to be of normal weight for height. 
Induction treatment:  at the start of induction treatment all subjects (100%) were found to be of 
normal weight for height. At the end of treatment two subjects (10%) were found to be 
overweight; both subjects grew in weight but not in height during this treatment phase therefore 
weight for height z-scores values found them to be overweight at the end of treatment. One 
subject was male from the 3-4 year age group diagnosed with standard risk Pre B cell ALL and 
the other subject was male from the 2-3 year age group diagnosed with standard risk B cell ALL. 
Consolidation treatment: at the start of consolidation treatment two subjects (10%) were found to 
be overweight however only one of these two subjects was overweight at the end of induction 
treatment; the other subject failed to grow in height during induction treatment which resulted in 
him being overweight. At the end of treatment all subjects (100%) were found to be of normal 
weight for height. The two subjects that were overweight at the start of treatment failed to grow 
in weight during this treatment phase therefore resulting in normal measurements.  
Interim maintenance treatment: at the start of interim maintenance treatment all subjects (100%) 
were found to be of normal weight for height. At the end of treatment one subject (5%) was 
found to be wasted; this occurred as a result of the parent insisting that enteral feeds be stopped 
mid-treatment. Episodes of mucositis and stomatitis prevented the subject from improving his 
oral intake. This subject was male from the 2-3 year age group diagnosed with standard risk B 
cell ALL. 
Delayed intensification treatment: at the start of delayed intensification treatment one subject 
(5%) was found to be wasted; this subject was also wasted at the end of the previous treatment 
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phase. At the end of treatment all subjects (100%) were found to be of normal weight for height. 
The subject that was stunted at the start of treatment was restarted on enteral feeds as the sole 
source of nutrition at the start of this treatment phase which improved his growth parameters.  
Maintenance treatment: at the start and end of maintenance treatment one subject (5%) was 
found to be overweight; this subject failed to grow in height due to congenital issues (Downs 
syndrome). At end of treatment a total of three subjects (15%) were found to be overweight (this 
includes the subject with Downs syndrome mentioned above and the other two subjects were 
found to gain between 15.2-20.6 % weight gain during this treatment phase. The subject with 
Downs syndrome was male from the 3-4 year age group diagnosed with standard risk B cell 
ALL; with regards to the other 2 subjects: both were male with one from the 3-4 year age group 
with high risk Pre B cell ALL) and the other was from 2-3 year age group with standard risk B 
cell ALL. 
4.3.3. BMI-for-age z-score 
At diagnosis: one subject (5%) was found to be underweight (this subject was male from the 1-2 
year age group diagnosed with standard risk B cell ALL) and one subject (5%) was found to be 
overweight (this subject was male from the 7-8 year age group diagnosed with standard risk T 
cell ALL). 
Induction treatment: at the start of induction treatment one subject (5%) was found to be 
underweight (this subject was male from the 1-2 year age group diagnosed with standard risk B 
cell ALL). Two subjects (10%) were found to be overweight at the start of treatment; one subject 
was male from the 7-8 year age group diagnosed with standard risk T cell ALL and the other 
subject was male from the 1-2 year age group diagnosed with standard risk Pre B cell ALL). At 
the end of treatment two subjects (10%) were found to be overweight; both subjects were of 
normal BMI at the start of treatment and during the course of treatment one followed a standard 
diet for age diet and the other followed a high calorie high protein diet plus consumed an oral 
nutritional supplement throughout treatment.  The subject that was overweight at diagnosis was 
of normal weight at the end of treatment due to poor weight gain and treatment-relatedside-
effects during treatment. One subject was male from the 3-4 year age group diagnosed with 
standard risk Pre B cell ALL and the other subject was male from the 2-3 year age group 
diagnosed with standard risk B cell ALL. 
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Consolidation treatment: at the start of consolidation treatment one subject (5%) was found to be 
overweight; this subject was also found to be overweight at the end of induction treatment; this 
subject was male from the 2-3 year age group diagnosed with standard risk B cell ALL. At the 
end of treatment all subjects (100%) were found to have normal BMI-for-age z –scores.  
Interim maintenance treatment: at the start of interim maintenance treatment one subject (5%) 
was found to be underweight due to poor gain in height during consolidation treatment; this 
subject was male from the 1-2 year age group diagnosed with standard risk B cell ALL. At the 
end of treatment this subject continued to be underweight in spite of initiating enteral feeds 
during the consolidation phase of treatment.  
Delayed intensification treatment: at the start of delayed intensification treatment one subject 
(5%) was identified as being underweight; this subject was also identified as underweight during 
interim maintenance treatment and this subject was also underweight at the end of this treatment 
phase in spite of initiating enteral feeds during the consolidation phase of treatment. This subject 
was male from the 1-2 year age group diagnosed with standard risk B cell ALL. 
Maintenance treatment: at the start of maintenance treatment one subject (5%) was found to be 
overweight; this subject was of normal BMI during the previous treatment phases; this subject 
was male with Downs syndrome from the 3-4 year age group diagnosed with standard risk B cell 
ALL. At the end of treatment two subjects (10%) were found to be overweight; one of which was 
overweight at the start of treatment. The other subject who was found to be overweight at the end 
of maintenance treatment had a normal BMI at the start of treatment but showed a 20.6% gain in 
weight at the end of treatment; subject was male from the 2-3 year age group diagnosed with 
standard risk B cell ALL. This subject was also started on a high calorie high protein diet with a 
high calorie high protein oral nutritional supplement from the consolidation phase of treatment 
until the end of delayed intensification treatment.  
4.3.4. Height-for-age z-scores   
At diagnosis: one subject (5%) was found to be stunted. This subject was male from the 1-2 year 
age group diagnosed with standard risk Pre B cell ALL. 
Induction treatment:  at the start and end of induction treatment one subject (5%) was found to 
be stunted. This subject was also stunted at diagnosis.  
Consolidation treatment: at the start and end of consolidation treatment two subjects (10%) were 
found to be stunted. One of the two subjects was stunted from diagnosis (this subject was male 
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from the 1-2 year age group diagnosed with standard risk Pre B cell ALL). The other subject was 
a one year old male diagnosed with standard risk B-cell ALL who failed to improve his growth 
due to treatment-related side-effects (anorexia accompanied by a food aversion). This negatively 
affected his nutritional intake in spite of commencing enteral feeds during the consolidation 
phase. 
Interim maintenance treatment: during interim maintenance treatment the two subjects (10%) 
who were found to be stunted at the end of the last treatment phase failed to grow in height 
during this phase and continued to be stunted. Also at the start and end of this treatment phase 
one subject (5%) was found to have a height-for-age above the norm (this subject was male from 
the 2-3 year age group diagnosed with standard risk B cell ALL). This subject was also receiving 
enteral feeding with a high calorie high protein formula as his sole source of nutrition during this 
treatment phase.  
Delayed intensification treatment: at the start and end of delayed intensification treatment one 
subject (5%) was found to be stunted; this subject failed to grow in height since diagnosis. At the 
start and end of treatment one subject (5%) was found to have a height-for-age above the norm; 
this subject continued to have above normal height-for-age measurements since the last treatment 
phase and was receiving enteral feeding with a high calorie high protein formula as his sole 
source of nutrition since interim maintenance treatment.  
Maintenance treatment: at the start and end of maintenance treatment one subject (5%) was 
found to be stunted; this subject failed to grow in height since diagnosis. At the end of treatment 
two subjects (10%) were found to have an above normal height-for-age; one of the two subjects 
were found to have an above normal height-for-age measurement since the interim maintenance 
phase and the other subject experienced a growth spurt during this phase as he was started on an 
enteral feed during the interim maintenance phase for having a poor oral intake (this subject was 
also male from the 2-3 year age group diagnosed with standard risk B cell ALL).   
In general, the distribution of anthropometric z-scores showed the highest percentage of stunting 
during the start and the end of the consolidation (10%) and the interim maintenance (10%) 
phases. A low percentage of subjects were underweight during all phases of treatment. The 
highest percentage of overweight was at the start (10%) and the end (10%) of induction 
treatment and at the end of maintenance treatment (10%). 
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4.4. Weight changes  
In this study, weight loss expressed as a percentage of body weight provided a more accurate 
estimate of the true significance of weight loss in subjects during cancer treatment 
(chemotherapy). A weight loss of greater than 5% of body weight over a period of one month is 
considered a sign of nutritional deprivation even when the subject is not classified as 
undernourished by anthropometric parameters (Bauer et al, 2011; Jeejeebhoy and Keith, 2005).   
Table 7 below represents the number of subjects that experienced weight and height changes at 
the end of each treatment phase.  
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Table 7: The number of subjects with weight and height changes at the end of each 
treatment phase 
Weight and 
height changes 
Induction 
Treatment  
Consolidation 
Treatment  
Interim 
Maintenance 
Treatment  
Delayed 
Intensification 
Treatment  
Maintenance 
Treatment  
Number of 
subjects with 
weight loss 
 
5 
 
16 
 
13 
 
4 
 
3 
Number of 
patients with > 
5% weight loss  
 
3 
 
8 
 
5 
 
0 
 
0 
Number of 
patients with 
weight gain 
 
14 
 
3 
 
6 
 
15 
 
15 
Number of 
subjects with > 
5% weight gain 
 
12 
 
1 
 
1 
 
7 
 
8 
Number of 
subjects with 
weight 
unchanged  
 
1 
 
1 
 
1 
 
1 
 
2 
Number of 
subjects with 
gain in height  
 
8 
 
7 
 
17 
 
12 
 
15 
Number of 
subjects with 
height 
unchanged  
 
12 
 
13 
 
3 
 
8 
 
5 
Number of 
subjects with 
gain in weight 
and height 
 
5 
 
2 
 
6 
 
8 
 
11 
 
Subjects experienced the highest weight loss during the consolidation phase and interim 
maintenance phases. The highest weight gain in subjects was observed during the induction, 
delayed intensification and maintenance phases of treatment. Subjects were found to show a gain 
in height during the interim maintenance, delayed intensification and maintenance phases of 
treatment.  
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Induction phase 
Weight-loss during induction treatment 
At the end of this treatment phase five subjects (25%) experienced a weight loss. One subject 
was male from the 1-2 year age group on treatment for standard risk ALL and was on a high 
calorie high protein diet plus an oral nutritional supplement, one subject was male from the 3-4 
year age group on treatment for standard risk ALL and received a high calorie high protein diet 
plus an oral nutritional supplement, one subject was male from the 11-12 year age group on 
treatment for high risk ALL and was on a high calorie high protein diet plus an oral nutritional 
supplement and one subject was male from the 11-12 year age group on treatment for high risk 
ALL and was on a normal calorie normal protein diet plus an oral nutritional supplement. There 
were multiple reasons for the weight loss which included anorexia, appetite changes, nausea, 
vomiting, taste changes and diarrhea.  
The subject with the highest weight loss percentage (10.9%) was a male belonging to the 1-2 
year age group and was on a high calorie high protein diet plus an oral nutritional supplement.  
Three subjects lost more than 5% of their body weight at the end of this treatment phase. One 
subject was male from the 1-2 year age group on treatment for standard risk ALL and was on a 
high calorie high protein diet plus an oral nutritional supplement, one subject was male from the 
3-4 year age group on treatment for standard risk ALL and received a high calorie high protein 
diet plus an oral nutritional supplement and one subject was male from the 11-12 year age group 
on treatment for high risk ALL and received a high calorie high protein diet plus an oral 
nutritional supplement. 
Weight gain during induction treatment 
Fourteen subjects experienced a weight gain at the end of this treatment phase. Two of the 
fourteen subjects were on a normal calorie normal protein diet, both subjects were male from the 
1-2 year age group on treatment for standard risk ALL. Seven of the fourteen subjects were on a 
high calorie high protein diet plus an oral nutritional supplement. Four of the seven subjects were 
from the 1-2 year age group (three were males and one was a female) on treatment for standard 
risk ALL, two of the seven subjects were from the 3-4 year age group (one was a male and one 
was a female) on treatment for standard risk ALL and one of the seven subjects was female from 
the 9-10 year age group on treatment for standard risk ALL. One of the fourteen subject was on a 
normal calorie normal protein diet plus an oral nutritional supplement from the 5-6 year age 
group (female) on treatment for standard risk ALL. Four of the fourteen subjects were on a high 
 
 
 
 
  
51 
calorie high protein diet plus an oral nutritional supplement plus enteral feed. Three subjects 
were from the 1-2 year age group (all subjects were male) on treatment for standard risk ALL 
and one subject was a male from the 3-4 year age group on treatment for high-risk ALL.  
Five of the fourteen subjects experienced a gain in weight and height at the end of this treatment 
phase. Three of the five subjects were on a high calorie high protein diet plus an oral nutritional 
supplement, one subject was a female from the 1-2 year age group and on treatment for standard 
risk ALL, one subject was a male from the 3-4 year age group and on treatment for standard risk 
ALL and one subject was a female from the 9-10 year age group and on treatment for standard 
risk ALL. One of the five subjects was a female on a normal calorie normal protein diet plus an 
oral nutritional supplement from the 5-6 year age group and on treatment for standard risk ALL. 
One of the five subjects was male on a high calorie high protein diet plus an oral nutritional 
supplement plus enteral feed from the 1-2 year age group and on treatment for standard-risk 
ALL. 
Twelve subjects gained more than 5% of their body weight at the end of this treatment phase. 
Two of the twelve subjects were male from the 3-4 year age group with one on treatment for 
Downs syndrome ALL (standard risk) and the other on treatment for high risk ALL; both 
subjects received a normal calorie normal protein diet. One of the twelve subjects was female 
from the 5-6 year age group on treatment for standard risk ALL and received a normal calorie 
normal protein diet plus oral nutritional supplements. Five of the twelve subjects received a high 
calorie high protein diet plus an oral nutritional supplement; three subjects were from the 1-2 
year age group and on treatment for standard risk ALL ( three were males and 2 were females). 
Four of the twelve subjects received a high calorie high protein diet plus an oral nutritional 
supplement plus an enteral feed; three subjects were male from the 1-2 year age group with three 
subjects on treatment for standard risk ALL and one subject on treatment for high risk ALL. 
Consolidation phase 
Weight-loss during consolidation treatment 
At the end of consolidation treatment a total of sixteen subjects (80%) experienced a weight loss 
of between 0.6 -10 % of their body weight. Three of the sixteen subjects received a normal 
calorie normal protein diet. Two of the sixteen subjects received a high calorie high protein diet. 
Seven of the sixteen subjects received a high calorie high protein diet plus an oral nutritional 
supplement; four of the seven subjects received this diet since the induction phase. Three of the 
sixteen subjects received an enteral feed as their sole source of nutrition. There were multiple 
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reasons for the weight loss which included anorexia, appetite changes, nausea, vomiting, taste 
changes, constipation, mucositis, stomatitis, pharyngitis, chemo-induced neuropathy (pain) and 
diarrhea.  
The subject with the greatest weight loss (10% of his body weight) was a male from the 7-8 year 
age group on a normal calorie normal protein diet since the induction phase and on treatment for 
standard-risk ALL.    
Eight subjects lost more than 5% of their body weight at the end of this treatment phase. Four of 
the eight subjects received a normal calorie normal protein diet; one subject was male from the 
1-2 year age group on treatment for standard risk ALL; one subject was male from the 3-4 year 
age group on treatment for high risk ALL (on the same diet since the induction phase); one 
subject was male from the 7-8 year age group on treatment for standard risk ALL (on the same 
diet since the induction phase) and one subject was male from the 11-12 year age group on 
treatment for high risk ALL. Two of the eight subjects received a high calorie high protein diet 
plus an oral nutritional supplement; one subject was female from the 5-6 year age group on 
treatment for standard risk ALL and one subject was male from the 11-12 year age group on 
treatment for high risk ALL. Both subjects received a normal calorie normal protein diet plus an 
oral nutritional supplement during the induction phase. One of the eight subjects received a high 
calorie high protein diet plus an oral nutritional supplement plus enteral feed; this subject was a 
male from the 3-4 year age group on treatment for standard risk ALL. This subject was on a high 
calorie high protein diet plus an oral nutritional supplement during the induction phase. One of 
the eight subjects received an enteral feed as a sole source of nutrition; this subject was a male 
from the 1-2 year age group on treatment for standard risk ALL. This subject was on a high 
calorie high protein diet plus an oral nutritional supplement plus enteral feed during the induction 
phase.  
Weight gain during the consolidation treatment 
Three subjects gained weight at the end of consolidation treatment. One of the three subjects was 
female from the 9-10 year age group and on treatment for standard-risk ALL who received a 
normal calorie normal protein diet during the induction phase. One of the three subjects was 
male from the 1-2 year age group and on treatment for standard-risk ALL who received a high 
calorie high protein diet plus an oral nutritional supplement plus enteral feed; this subject was on 
a high calorie high protein diet plus an oral nutritional supplement during the induction phase. 
One of the three subjects received an enteral feed as a sole source of nutrition; this subject was a 
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male from the 1-2 year age group on treatment for standard risk ALL and was on a high calorie 
high protein diet plus an oral nutritional supplement plus enteral feed during the induction phase. 
Two of the three subjects experienced a gain in weight and height at the end of this treatment 
phase. 
One subject gained more than 5% of their body weight at the end of this treatment phase; this 
subject was male from the 1-2 year age group and on treatment for standard-risk ALL who 
received a high calorie high protein diet plus an oral nutritional supplement plus enteral feed and 
was on a high calorie high protein diet plus an oral nutritional supplement during the induction 
phase. This subject also increased in stature. 
Interim maintenance treatment 
Weight loss during interim maintenance treatment  
Thirteen subjects (65%) lost weight at the end of this treatment phase. Five of the thirteen 
subjects received a normal calorie normal protein diet; three of the five subjects were on the 
same diet since the induction phase and the remaining two subjects were started on this diet since 
the consolidation phase. Five of the thirteen subjects received a high calorie high protein diet 
plus an oral nutritional supplement; three of the five subjects received this diet since the 
induction phase. Three of the thirteen subjects received an enteral feed as their sole source of 
nutrition and received this diet since the consolidation phase.  
There were multiple reasons for the weight loss which included anorexia, appetite changes, 
nausea, vomiting, taste changes, constipation, mucositis, stomatitis, pharyngitis, chemo-induced 
neuropathy (pain) and diarrhea.  
The subject with the highest weight loss percentage (13.9%) was a male from the 1-2 year age 
group and on treatment for standard-risk ALL who received a normal calorie normal protein diet 
since the consolidation phase. 
Five of the thirteen subjects lost more than 5% of their body weight at the end of this treatment 
phase. Two of the five subjects received a normal calorie normal protein diet; one subject was 
male from the 1-2 year age group on treatment for standard risk ALL and the other subject was 
female from the 9-10 year age group on treatment for standard risk ALL. Two of the five 
subjects received a high calorie high protein diet plus an oral nutritional supplement; one subject 
was female from the 5-6 year age group on treatment for standard risk ALL (on the same diet 
since the consolidation phase) and one subject was male from the 3-4 year age group on 
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treatment for standard risk ALL (on the same diet since the induction phase). One of the five 
subjects was a male from the 1-2 year age group on treatment for standard risk ALL and 
receiving enteral feeds as his sole source of nutrition; this subject was on the same diet since the 
consolidation phase. 
Weight gain during the interim maintenance phase 
Six subjects gained weight at the end of this treatment phase. Three of the six subjects received a 
high calorie high protein diet plus an oral nutritional supplement; two of the three subjects were 
male from the 1-2 year age group on treatment for standard risk ALL and one of the subjects was 
male from the 11-12 year age group on treatment for high risk ALL. Two of the six subjects 
received a high calorie high protein diet plus an oral nutritional supplement plus enteral feed; one 
subject was male from the 1-2 year age group on treatment for standard risk ALL and one 
subject was male from the 3-4 year age group on treatment for standard risk ALL. One of the six 
subjects received an enteral feed as their sole source of nutrition; the subject was male from the 
1-2 year age group on treatment for standard risk ALL and on this diet since the consolidation 
phase. All six subjects experienced a gain in weight and height at the end of this treatment phase. 
One subject gained more than 5% of his body weight at the end of this treatment phase; the 
subject was male from the 3-4 year age group on treatment for standard risk ALL and received a 
high calorie high protein diet plus an oral nutritional supplement plus enteral feed since the 
consolidation phase. 
Delayed intensification phase 
Weight loss during delayed intensification treatment 
At the end of delayed intensification treatment four subjects (20%) lost weight. One of the four 
subjects was male from the 7-8 year age group and on treatment for standard risk who received a 
normal calorie normal protein diet; this subject was on the same diet since the start of treatment. 
One of the four subjects was male from the 11-12 year age group and on treatment for high risk 
who received a high calorie high protein diet plus an oral nutritional supplement; this subject was 
on the same diet since the start of treatment. The remaining two subjects received an enteral feed 
as their sole source of nutrition subject;  one of the two subjects was male from the 1-2 year age 
group on treatment for standard risk ALL and the other subject was female from the 3-4 year age 
group on treatment for high risk ALL. Both subjects received an enteral feed as their sole source 
of nutrition since the consolidation phase. 
 
 
 
 
  
55 
None of the subjects experienced a weight loss greater than 5% of their body weight at the end of 
this treatment phase.  
Weight gain during delayed intensification treatment 
At the end of this phase fifteen subjects (75%) gained weight. Four of the fifteen subjects 
received a normal calorie normal protein diet. One of the four subjects was a male from the 1-2 
year age group on treatment for standard risk ALL. Two of the four subjects were male from the 
3-4 year age (one subject was on treatment for Downs syndrome standard risk ALL and the other 
subject was on treatment for high risk ALL). Nine of the fifteen subjects received a high calorie 
high protein diet plus an oral nutritional supplement. Four of the nine subjects were from the 1-2 
year age group (three males and one female) on treatment for standard risk ALL. Three of the 
nine subjects were from the 3-4 year age group (two males and one female) on treatment for 
standard risk ALL. One of the nine subjects was a female from the 5-6 year age group on 
treatment for standard risk ALL. One of the nine subjects was a female from the 9-10 year age 
group on treatment for standard risk ALL. One of the fifteen subjects was male from the 1-2 year 
age group and on treatment for standard risk ALL who received an enteral feed as his sole source 
of nutrition since the consolidation phase. Eight of the fifteen subjects experienced a gain in 
weight and height at the end of this treatment phase. 
Seven subjects (35%) gained more than 5% of their body weight at the end of this treatment 
phase. One of the seven subjects received a normal calorie normal protein diet. Five of the seven 
subjects received a high calorie high protein diet plus an oral nutritional supplement. One of the 
five subjects received an enteral feed as his sole source of nutrition since the consolidation phase.  
Maintenance treatment 
Weight loss during maintenance treatment 
At the end of maintenance treatment three subjects (15%) experienced a weight loss of between 
0.6 – 0.9%. None of these subjects experienced a significant weight loss of greater than 5% of 
their body weight.  
Weight gain during maintenance treatment 
At the end of maintenance treatment fifteen subjects (75%) experienced a weight gain of 
between 0.9-20.6 percent. Nine of the fifteen subjects received a normal calorie normal protein 
diet. Five of the fifteen subjects received a high calorie high protein diet plus an oral nutritional 
supplement. One of the fifteen subjects received a high calorie high protein diet plus an oral 
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nutritional supplement plus an enteral feed. Eleven of the fifteen subjects experienced a gain in 
weight and height at the end of this treatment phase. 
Eight subjects (40%) gained more than 5% of their body weight at the end of this treatment 
phase. Five of the eight subjects received a normal calorie normal protein diet. Two of the eight 
subjects received a high calorie high protein diet plus an oral nutritional supplement. One of the 
eight subjects received a high calorie high protein diet plus an oral nutritional supplement plus an 
enteral feed.  
In summary a significant weight loss of more than 5% of body weight was observed in subjects 
on the following diets at the end of each treatment phase:  
Induction treatment 
At the end of the induction phase three out of eleven subjects lost more than 5% of their body 
weight on a high calorie high protein diet plus an oral nutritional supplement. 
Consolidation treatment  
At the end of the consolidation phase three out of five subjects lost more than 5% of their body 
weight on a normal calorie normal high protein diet.  
At the end of the consolidation phase three out of seven subjects lost more than 5% of their body 
weight on a high calorie high protein diet plus an oral nutritional supplement.  
At the end of the consolidation phase one out of two subjects lost more than 5% of their body 
weight on a high calorie high protein diet plus an oral nutritional supplement plus enteral feed. 
At the end of the consolidation treatment one out of four subjects lost more than 5% of their 
body weight on an enteral feed as a sole source of nutrition. 
Interim maintenance treatment  
At the end of interim maintenance treatment two out of five subjects lost more than 5% of their 
body weight on a normal calorie normal high protein diet.  
At the end of the interim maintenance treatment two out of nine subjects lost more than 5% of 
their body weight on a high calorie high protein diet plus an oral nutritional supplement.  
At the end of the interim maintenance treatment none of the subjects lost more than 5% of their 
body weight on a high calorie high protein diet plus an oral nutritional supplement plus enteral 
feed.  
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At the end of interim maintenance treatment one out of four subjects lost more than 5% of their 
body weight on an enteral feed as a sole source of nutrition. 
 Delayed intensification treatment 
At the end of delayed intensification treatment none of the patients receiving nutrition support 
were found to lose more than 5% of their body weight.  
Maintenance treatment 
At the end of maintenance treatment none of the patients receiving nutrition support were found 
to lose more than 5% of their body weight.  
It can therefore be concluded that pediatric subjects receiving nutritional support during 
treatment for ALL underwent changes in nutritional status as manifest by a reduction in more 
than 5% of their body weight during three phases of treatment namely induction, consolidation 
and interim maintenance.  
4.5. Biochemistry 
Laboratory measurements that are most frequently used to assess the nutritional status of 
children in this study included albumin, blood glucose levels and hemoglobin.  
Table 8 below shows the incidence of hypoalbuminemia, hyperglycemia and anemia at the end 
of each treatment phase 
Table 8: The incidence of hypoalbuminemia, hyperglycemia and anemia at the end of each 
treatment phase 
Biochemical data 
at the end of each 
treatment phase 
Induction 
treatment  
(% of subjects ) 
Consolidation 
Treatment  
(% of subjects ) 
Interim 
Maintenance 
Treatment  
(% of subjects ) 
Delayed 
Intensification 
Treatment  
(% of subjects ) 
Maintenance 
Treatment  
(% of subjects ) 
Hypoalbuminemia 65 50 35 45 15 
Hyperglycemia 10 0 15 0 15 
Low hemoglobin 85 95 75 85 70 
 
4.5.1. Hypoalbuminemia  
With regards to biochemistry the highest incidence of hypoalbuminemia was found at the end of 
induction treatment in 13 subjects (65%); 9 subjects were male with the highest occurrence 
within the 3-4 year age group. Ten subjects (50%) had hypoalbuminemia at the end of 
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consolidation treatment; 8 subjects were male with the highest occurrence within the 3-4 year 
age group. 
4.5.2. Hyperglycemia  
Two subjects (10%) experienced hyperglycemia at the end of induction treatment; one subject 
was male form the 11-12 year age group and one subject was female from the 9-10 year age 
group. Three subjects (15%) experienced hyperglycemia at the end of interim maintenance 
treatment; all subjects were male with the highest occurrence from the 3-4 year age group. The 
subject with Downs’s syndrome ALL experienced hyperglycemia at the end of interim 
maintenance treatment. Three subjects (15%) experienced hyperglycemia at the end of 
maintenance treatment; all subjects were male with the highest occurrence within the 1-2 year 
age group. There were no reports of subjects having hyperglycemia at the end of consolidation 
treatment and delayed intensification treatment.  
4.5.3. Anemia  
Low hemoglobin levels were experienced by the majority of subjects at the end of all treatment 
phases. At the end of consolidation treatment 19 subjects (95%) were anemic; 14 of the 19 
subjects were male with the highest occurrence equally divided within the 1-2 year and 3-4 year 
age groups.  
4.6. Treatment delays 
Table 9 below shows the most common reasons for treatment delays between the different 
phases of treatment expressed as a percentage of subjects.  
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Table 9: Reasons for treatment delays between treatment phases  
Reasons for  
Treatment Delays  
Consolidation 
Treatment  
(% of subjects ) 
Interim 
Maintenance 
Treatment  
(% of subjects ) 
Delayed 
Intensification 
Treatment  
(% of subjects ) 
Maintenance 
Treatment  
(% of subjects ) 
Low ANC 25 25 5 15 
Diarrhea 10 - - - 
Rash  5 - - - 
Fever 5 25 - - 
Vomiting  5 - - - 
Thrombocytopenia  - 5 - - 
URTI 5 - - - 
High liver enzymes - - - 5 
ANC – absolute neutrophil count, URTI – upper respiratory tract infection 
  
Consolidation treatment  
At the start of consolidation treatment 4 subjects (25%) experienced treatment delays as a result 
of neutropenia; all the subjects were male with the highest occurrence in the 1-2 year and 3-4 
year age groups. Two subjects (10%) experienced treatment delays as a result of diarrhea; all 
subjects were male with equal occurrence within the 1-2 year and 11-12 year age groups. Fever, 
skin rash, vomiting and upper respiratory infection accounted for 5% of the treatment delays 
experienced by subjects during this treatment phase.    
Interim maintenance treatment   
At the start of interim maintenance treatment 4 subjects (25%) experienced treatment delays as a 
result of neutropenia and fever; all the subjects were male with the highest occurrence in the 1-2 
year and 3-4 year age groups. One subject (5%) experienced a treatment delay as a result of 
thrombocytopenia; the subject was a male in the 7-8 year age group.  
Delayed intensification treatment 
At the start of delayed intensification treatment one subject (5%) experienced a treatment delay 
due to neutropenia; the subject was male in the 1-2 year age group. 
Maintenance treatment 
At the start of maintenance treatment 3 subjects (15%) experienced a treatment delay due to 
neutropenia; the subjects were all male with highest incidence in the 1-2 year and 3- 4 year age 
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groups. One subject (5%) experienced a treatment delay due to elevated liver enzymes; the 
subject was female in the 1-2 year age group. 
In summary treatment delays occurred as a result of neutropenia, diarrhea, skin rash, fever, 
vomiting, thrombocytopenia, upper respiratory tract infection and elevation in liver enzymes 
with the most common reasons for treatment delay between treatment phases being neutropenia, 
diarrhea and fever. 
4.7. Treatment-related complications 
Table 10 below shows the clinical and systemic complications during the different treatment. 
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Table 10: The clinical and systemic complications during the different treatment phases  
Clinical & systemic 
complications   
Induction 
treatment  
(% of subjects ) 
Consolidation 
Treatment  
(% of subjects ) 
Interim 
Maintenance 
Treatment 
(% of subjects ) 
Delayed 
Intensification 
Treatment  
(% of subjects ) 
Maintenance 
Treatment  
(% of subjects ) 
Anorexia 15 15 35 5 - 
Appetite changes  70 35 5 15 - 
Bone pain 20 - 35 - - 
Chemo-induced 
neuropathy 
- 10 - 5 - 
Constipation 5 10 15 5 - 
Diarrhea 
 
25 10 5 5 - 
Fever 5 20 15 25 - 
Hyperglycemia 10 - - - - 
Hypertension 
 
5 - - - - 
Liver-enzymes 
elevated 
- 5 - - - 
Mucositis  - 10 15 15 - 
Nausea 60 20 15 - - 
Neutropenia - 25 15 25 5 
Pharyngitis - 5 - - - 
Peri-orbital 
swelling  
- 5 - - - 
Perianal ulcer - - - 5 - 
Platelets (low) 20 - - - - 
Skin reaction - - 10 - - 
Stomatitis - 10 15 15 - 
Taste changes  10 5 5 10 - 
Tumor-lysis 
syndrome 
10 - - - - 
Vomiting 60 45 25 10 - 
Zoster infection - - - 5 - 
 
 
 
 
 
 
 
 
  
62 
nduction treatment  
The most common side-effects experienced during the induction phase were appetite changes in 
14 subjects (70%); most subjects were male with the highest occurrence within the 1-2 year and 
3-4 year age groups.   
Twelve subjects (60%) experienced nausea and vomiting; most subjects were male with the 
highest occurrence in the 1-2 year and 3-4 year age groups. 
Four subjects (20%) experienced diarrhea; most subjects were male with the highest occurrence 
in the 1-2 year age group. All female subjects that experienced diarrhea were also from the 1-2 
year age group.  
Four subjects (20%) experienced bone pain during induction treatment; most subjects were male 
with the highest occurrence 3-4 year age group. Most female subjects that experienced bone pain 
were also from the 3-4 year age group.  
Four subjects (20%) experienced a low platelet count during induction treatment. All of which 
were males with the highest occurrence in 3-4 year age group.  
Two subjects (10%) experienced tumor lysis syndrome during this phase; all subjects were male 
with equal occurrence in 7-8 year and 11-12 year age groups. The subject in the 11-12 year age 
group was receiving treatment for high risk ALL. 
Consolidation treatment  
During the consolidation phase the most common side effect experienced was vomiting in 9 
subjects (45%); most subjects were male with the highest occurrence in the 1-2 year and  3- 4 
year age groups.  
Seven subjects (35%) experienced appetite changes; most subjects were male the highest 
occurrence in the 3- 4 year age group.  
Four subjects (20%) experienced neutropenia; all subjects were male with the highest occurrence 
in the 1-2 year age group.  
Mucositis and stomatitis was experienced in two subjects (10 %); all subjects were male with 
equal distribution within the 1-2 year and 7-8 year age groups. 
Chemotherapy induced neuropathy was experienced by two subjects (10%) during the 
consolidation phase; all subjects were male with equal distribution within the 1- 2 year and 3-4 
year age groups.      
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Interim maintenance treatment 
During the interim maintenance phase seven subjects (35%) experienced anorexia; most subjects 
were male with the highest occurrence in the 1-2 year age group.   
Five subjects (25%) experienced bone pain; all subjects were male with the highest occurrence in 
the 1-2 year age group. 
Five subjects (25%) experienced vomiting; all subjects were male with the highest occurrence in 
the 1-2 year age group. 
Three subjects (15%) experienced neutropenia; the subjects were mostly female with the highest 
occurrence in the 3-4 year age group. 
Mucositis and stomatitis was experienced in three subjects (15 %); the subjects were mostly male 
with equal distribution within the 1-2 year and 11-12 year age groups. 
Delayed intensification treatment  
During the delayed intensification phase fever was experienced by four subjects (25%); the 
subjects were mostly male with the highest occurrence in the 1-2 year age group. 
Twenty five percent of subjects experienced neutropenia; 80 % of subjects were male with the 
highest occurrence in the 1-2 year age group. 
Three subjects (15%) experienced appetite changes; the subjects were mostly female with the 
highest occurrence in the 1-2 year age group. 
Chemotherapy induced neuropathy was experienced by one subject (5%); the subject was male 
and belonged to the 1-2 year age group (this subject also experienced chemotherapy induced 
neuropathy during consolidation treatment.   
Mucositis and stomatitis was experienced in 3 subjects (15 %); all subjects were male with 
highest occurrence in the 1-2 year age group. 
Maintenance treatment  
The only treatment-related side effect reported during the maintenance phase was neutropenia in 
one subject (5%); the subject was male and from the 3-4 year age group. 
In summary subjects experienced the greatest number of treatment-related complications during 
the induction, consolidation, interim maintenance, delayed intensification phases of treatment 
and the lowest number during the maintenance phase. During the induction phase the most 
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common nutritionally related complications were appetite changes, nausea, vomiting, diarrhea, 
anorexia, hyperglycemia, taste changes, tumor lysis syndrome and constipation. During the 
consolidation phase the most common nutritionally related complications were appetite changes, 
nausea, vomiting, diarrhea, anorexia, taste changes, constipation, mucositis, stomatitis and 
pharyngitis. During the interim maintenance phase the most common nutritionally related 
complications were appetite changes, nausea, vomiting, diarrhea, anorexia, taste changes, 
constipation, mucositis and stomatitis. During the delayed intensification phase the most 
common nutritionally related complications were appetite changes, vomiting, diarrhea, anorexia, 
taste changes, constipation, mucositis and stomatitis. During the maintenance phase there was an 
absence of nutritionally related complications.   
4.8. Diet order and nutritional support 
At the start of treatment all subjects were prescribed an age-appropriate diet with two snacks as 
all subjects were found to be of normal weight and height-for-age. Table 7 below reports the diet 
prescription of subjects during the different treatment phases.  
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Table 11: The diet prescription of subjects during the different treatment phases   
Diet prescription 
during the 
different 
treatment phases 
Induction 
treatment  
(No. of subjects)  
Consolidation 
Treatment  
(No. of subjects) 
Interim 
Maintenance 
Treatment  
(No. of subjects) 
Delayed 
Intensification 
Treatment  
(No. of subjects) 
Maintenance 
Treatment  
(No.  of subjects) 
Subjects receiving  
normal calorie and 
protein diet only 
 
3 5 5 6 13 
Subjects receiving a 
high calorie and 
high protein diet 
only  
 
0 2 0 0 0 
Subjects receiving  
normal calorie and  
protein diet + oral 
nutritional 
supplement 
 
2 0 0 0 0 
Subjects receiving a 
high calorie and 
high protein diet + 
oral nutritional 
supplement 
 
11 7 9 11 5 
Subjects receiving a 
high calorie and 
high protein diet + 
oral nutritional 
supplement + 
transitioned to an 
enteral feed  
 
4 2 2 0 2 
Enteral feeds only 
 
0 4 4 3 0 
 
Induction treatment 
Normal calorie normal protein diet 
During the induction phase three subjects (15%) received a normal calorie normal protein diet. 
All subjects were male with two subjects from the 3- 4 year age group (one subject was on 
treatment for high risk ALL and the other subject was on treatment for Downs syndrome 
standard risk ALL) and one subject was from the 7-8 year age group on treatment for standard 
risk ALL.  
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The remaining seventeen subjects were transitioned on to energy dense diets with or without oral 
nutritional supplement and /or an enteral feed due to weight loss which resulted from treatment-
related side-effects outlined in Table 6.    
Normal calorie normal protein diet plus an oral nutritional supplement 
Two subjects (10%) were prescribed a normal calorie normal protein diet plus an oral nutritional 
supplement due to poor weight gain. One subject was male from the 11-12 year age group on 
treatment for high risk ALL and the other subject was female from the 5-6 year age group on 
treatment for standard risk  
High calorie high protein diet plus an oral nutritional supplement 
Eleven subjects (55%) were prescribed a high calorie high protein diet plus an oral nutritional 
supplement. Four subjects were from the 1-2 year age group on treatment for standard risk (3 
males and 1 female), four subjects were from the 3-4 year age group on treatment for standard 
risk (2 males and 2 female), one subject was from the 9-10 year age group on treatment for 
standard risk ALL and one subject was from the 11-12 year age group on treatment for high risk 
ALL. 
High calorie high protein diet plus an oral nutritional supplement plus an enteral feed 
Four subjects (20%) were prescribed a high calorie high protein diet plus an oral nutritional 
supplement plus an enteral feed. Three subjects were from the 1-2 year age group on treatment 
for standard risk (all male) and one subject was male from 3-4 year age group on treatment for 
high risk ALL.  
Consolidation treatment 
Normal calorie normal protein diet 
During the consolidation phase five subjects (25%) received a normal calorie normal protein 
diet. One subject was male from the 1-2 year age group on treatment for standard risk, two 
subjects were male from the 3-4 year age group on treatment for standard risk, one subject was 
male from the 7-8 year age group on treatment for standard risk ALL and one subject was male 
from the 9-10 year age group on treatment for high risk ALL. 
Three of the five subjects (15%) who received a normal calorie normal protein diet during the 
induction phase continued on this diet prescription during the consolidation phase, as they were 
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able to maintain normal anthropometric measurements however all three patients failed to grow 
in weight and height during this phase.  
The remaining two subjects (10%), one male from the 1-2 year age group on treatment for 
standard risk ALL with significant weight gain during the induction phase (8% of body weight) 
and one female from the 9-10 year age group on treatment for standard risk ALL also with 
significant weight gain during the induction phase (3.7% of body weight) were transitioned from 
a high calorie high protein diet with supplements to a normal calorie normal protein diet with no 
supplements.  
High calorie high protein diet without an oral nutritional supplement  
Two subjects (10%) received a high calorie high protein diet without oral nutritional 
supplements. One subject was male from the 1-2 year age group on treatment for standard risk 
ALL and one subject was female from the 3-4 year age group on treatment for standard risk 
ALL. Both subjects were transitioned from a high calorie high protein diet with supplements 
during the induction phase to a high calorie high protein diet without oral nutritional supplements 
during the consolidation phase due to a positive weight gain percentages of 12% and 18% 
respectively.  
High calorie high protein diet with an oral nutritional supplement 
Seven subjects (35%) were prescribed a high calorie high protein diet in addition to an oral 
nutritional supplement. Two subjects were from the 1-2 year age group on treatment for standard 
risk (one male and one female), two subjects were from the 3-4 year age group on treatment for 
standard risk (one male and one female), one subject was female from the 5-6 year age group on 
treatment for standard risk ALL and two subjects were males from the 11-12 year age group on 
treatment for high risk ALL. 
Five of the six subjects remained on this diet prescription since the induction phase; two subjects 
were from the 1-2 year age group on treatment for standard risk (one male and one female), two 
subjects were from the 3-4 year age group on treatment for standard risk (one male and one 
female) and one subject was male from the 11-12 year age group on treatment for high risk ALL. 
High calorie high protein diet plus an oral nutritional supplement plus an enteral feed 
Two subjects (10%) were prescribed a high calorie high protein diet plus an oral nutritional 
supplement plus an enteral feed during this phase. One subject was male from the 1-2 year age 
group on treatment for standard risk ALL and one subject was male from the 3-4 year age group 
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on treatment for standard risk ALL. Both subjects were previously on a high calorie high protein 
diet plus an oral nutritional supplement during the induction phase; enteral feeds were started as 
a result of a poor oral intake resulting in a weight loss of 10.9-12 % of their body weight.  
Enteral feed only 
Four subjects (20%) received an enteral feed as a sole source of nutrition during this phase. All 
subjects in this group were on a high calorie normal high protein diet in addition to an oral 
nutritional supplement plus an enteral feed during the induction phase. As a result of vomiting, 
mucositis and stomatitis these subjects developed a food aversion and were unable to meet their 
nutritional needs orally. All subjects were male on treatment for standard risk ALL; three 
subjects were from the 1-2 year age group and one subject was from the 3-4 year age group. 
Interim maintenance treatment 
Normal calorie normal protein diet 
During the interim maintenance phase five subjects (25%) received a normal calorie normal 
protein diet. One subject was male from the 1-2 year age group on treatment for standard risk, 
two subjects were male from the 3-4 year age group on treatment for standard risk, one subject 
was male from the 7-8 year age group on treatment for standard risk ALL and one subject was 
male from the 9-10 year age group on treatment for high risk ALL. 
All five subjects remained on this diet prescription since the consolidation phase in spite of three 
of the five subjects having a weight loss percentage greater than 5% of their body weight at the 
end of the consolidation phase.  
High calorie high protein diet plus an oral nutritional supplement 
Nine subjects (45%) were prescribed a high calorie high protein diet plus an oral nutritional 
supplement. Three subjects were from the 1-2 year age group on treatment for standard risk (two 
males and one female), three subjects were from the 3-4 year age group on treatment for standard 
risk (one male and two females), one subject was female from the 5-6 year age group on 
treatment for standard risk ALL and two subjects were males from the 11-12 year age group on 
treatment for high risk ALL. 
Seven of the nine subjects remained on this diet prescription since the consolidation phase due to 
a poor weight gain during the consolidation phase. 
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High calorie high protein diet plus an oral nutritional supplement plus an enteral feed 
Two subjects (10%) were prescribed a high calorie high protein diet plus an oral nutritional 
supplement plus an enteral feed during this phase. Both subjects remained on this diet 
prescription since the consolidation phase due to a poor oral intake as a result of treatment-
related side-effects, both subjects were male with one from the 1-2 year age group with standard 
risk ALL and the other one from the 3-4 year age group also with standard risk ALL.  
Enteral feed only 
Four subjects (20%) received an enteral feed as a sole source of nutrition during this phase. All 
four subjects remained on this diet prescription since the consolidation phase due to a food 
aversion as a result of vomiting, mucositis and stomatitis. Two of the four subjects experienced a 
weight loss during this phase but gained height while one of the remaining two subjects gained 
weight and height during this treatment phase.  
Delayed intensification treatment 
Normal calorie normal protein diet 
During the delayed intensification phase six subjects (30%) received a normal calorie normal 
protein diet. One subject was male from the 1-2 year age group on treatment for standard risk, 
three subjects were from the 3-4 year age group (two male and one female) with two subjects 
was on treatment for standard risk ALL and one subject on treatment for high risk ALL; one 
subject was male from the 7-8 year age group on treatment for standard risk ALL and one 
subject was male from the 9-10 year age group on treatment for high risk ALL. 
Three of the six subjects remained on this diet prescription since the interim maintenance phase. 
The remaining three of the six subjects were on a high calorie high protein diet plus an oral 
nutritional supplement during the interim maintenance phase. Two the three subjects, one male 
from the 1-2 year age group on treatment for standard risk ALL and one male from the 11-12 
year age group on treatment for high risk ALL, gained weight and height during the interim 
maintenance phase and was transitioned on to a normal calorie normal protein diet during this 
phase. 
High calorie high protein diet with an oral nutritional supplement 
Eleven subjects (55%) were prescribed at high calorie high protein diet plus an oral nutritional 
supplement during this phase. Four subjects were from the 1-2 year age group on treatment for 
standard risk ALL (three males and one female), three subjects were from the 3-4 year age group 
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on treatment for standard risk ALL (two males and one female), one subject was from the 5-6 
year age group on treatment for standard risk ALL (female) and one subject was from the 11-12 
year age group on treatment for high risk ALL (male). 
Six of the eleven subjects remained on this diet prescription since the interim maintenance phase.  
Enteral feed only 
Three subjects (15%) received an enteral feed as a sole source of nutrition during this phase. All 
three subjects remained on this diet prescription since the consolidation phase due to a food 
aversion as a result of vomiting, mucositis and stomatitis and did not gain weight during the 
interim maintenance phase. Two subjects were male from the 1-2 year age group on treatment 
for standard risk ALL and one subject was a male from the 3-4 year age group on treatment for 
high risk ALL. 
Maintenance treatment  
Normal calorie normal protein diet 
During the maintenance phase thirteen subjects (65%) received a normal calorie normal protein 
diet. Four subjects were male from the 1-2 year age group on treatment for standard risk ALL, 
six subjects (four males and two females) were from the 3-4 year age group (five subjects were 
on treatment for standard risk ALL and one subject was on treatment for high risk ALL), one 
subject was male from the 7-8 year age group on treatment for standard risk ALL, one subject 
was female from the 9-10 year age group on treatment for standard risk ALL and one subject 
was male from the 11-12 year age group on treatment for high risk ALL. 
Six of the thirteen subjects remained on this diet prescription since the delayed intensification 
phase. The remaining seven subjects were on a high calorie high protein diet plus an oral 
nutritional supplement during delayed intensification phase and were transitioned on to a normal 
calorie normal protein diet during this phase due to a significant gain in weight. 
High calorie high protein diet plus an oral nutritional supplement 
Five subjects (25%) were prescribed a high calorie normal high protein diet in addition to an oral 
nutritional supplement. Three subjects were from the 1-2 year age group on treatment for 
standard risk ALL (two were males and one was a female), one subject was a female from the 5-
6 year age group on treatment for standard risk ALL and one subject was male from the 11-12 
year age group on treatment for high risk ALL. 
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Four of the five subjects remained on this diet prescription since the delayed intensification 
phase and all subjects had a weight gain on this diet plan at the end of maintenance treatment. 
The remaining subject was transitioned from an enteral feed (as a sole source of nutrition) during 
the delayed intensification phase to a high calorie high protein diet plus an oral nutritional 
supplement during this phase as he had gained more than 5% of his body weight. This subject 
was a male from the 11-12 year age group and also gained weight and height at the end of the 
maintenance phase.   
High calorie high protein diet plus an oral nutritional supplement plus an enteral feed 
Two subjects (10%) were transitioned from an enteral feed (as a sole source of nutrition) to high 
calorie normal high protein diet plus an oral nutritional supplement plus an enteral feed during 
this phase. Both subjects were male; one was from the 1-2 year age group (on standard risk 
treatment for ALL) and the other subject was from the 3-4 year age group (on high risk treatment 
for ALL). The subject from the 1-2 year age group lost weight but gained height at the end of 
this treatment phase. The subject from the 3-4 year age group (on high risk treatment for ALL) 
gained weight and height at the end of this treatment phase. 
In summary nutrition support in the form of a normal calorie normal protein diet plus an oral 
nutritional supplement occurred only during the induction phase. Nutrition support in the form of 
a high calorie high protein diet plus an oral nutritional supplement occurred mostly during the 
induction, consolidation, interim maintenance, delayed intensification and maintenance phases of 
treatment. Nutrition support in the form of a high calorie high protein diet plus an oral nutritional 
supplement plus enteral feed occurred mostly during the induction, consolidation, interim 
maintenance and maintenance phases of treatment. Nutrition support in the form of enteral 
feeding as a sole source of nutrition occurred mostly during the consolidation, interim 
maintenance and delayed intensification phases of treatment. 
4.9. Remission  
At the end of induction treatment a total of eighteen subjects (90%) were reported to have 
achieved remission. Two subjects (10%) did not achieve remission, both subjects were male and 
received treatments for high risk ALL and belonged to the 3-4 year and 11-12 year age groups.  
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Introduction  
All subjects included in this study were diagnosed with the same type of cancer (acute 
lymphoblastic leukemia) and received the same type of cancer treatment (chemotherapy) under 
the same treatment protocols and policies. The data gathering for all subjects in this study was 
therefore the same.     
5.1. Symptoms at diagnosis 
In this study the most common clinical characteristics at diagnosis was fever without any 
evidence of infection, purpuric bruises, flu-like symptoms, anemia, weight loss, bone pain as a 
result of an infiltration of the bone marrow by a large number of leukemic cells and epistaxis. A 
Middle Eastern study by Al-Mulla et al (2014) reported the prevalence of bone pain amongst the 
signs and symptoms upon presentation of ALL as being higher than in western countries. 
Another study by Salim et al (2014) on pediatric ALL cases reported pallor as the most common 
symptom of ALL at diagnosis followed by fever, bone pain, lethargy, fatigue and a loss in 
appetite. The comparison of these results with other studies is limited due to a lack of published 
studies. 
5.2. Characteristics at diagnosis 
The peak age of diagnosis in this study was between the ages of 1 to 2 years old. Although there 
is a lack of published studies in the United Arab Emirates on the incidence of pediatric ALL, the 
Middle Eastern study conducted by Al-Mulla et al (2014) on 1150 pediatric patients with ALL 
found the peak age range of children at diagnosis to be between 3-6 years of age which was 
similar to the age range reported in western countries. Another study by Lughetti et al (2012) 
reported the peak age of ALL occurrences in children to be between the ages of 2- 6 years of age.  
The most common type of ALL amongst subjects in this study was B-cell ALL which was 
similar to the findings of Al-Mulla et al (2014).  
The ratio for males to females in this study was calculated to be 3:1 which was different from the 
sex-based incidence ratio of 1.4: 1 (males: females) reported by Al-Mulla et al (2014). Other 
studies published by The Cancer Oncology Group (2015) and an earlier study by Gholami et al 
(2013) reported the prevalence of ALL to be slightly more common in males than females 
though the reason for this was unknown.  
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In this study, B-cell ALL was found in 60% of subjects and T-cell ALL was found in 10% of 
subjects. Five percent of subjects with T-cell ALL had testicular involvement. Five percent of the 
total subjects included in the study was diagnosed with Trisomy 21(Downs syndrome) B-cell 
ALL. The Cancer Oncology Group (2015) reported similar findings; B-cell ALL was reported to 
be the most common type ALL in children (80-85% of children with ALL) and T-cell is a less 
common type (15-20% of children with ALL); and testicular involvement in males was reported 
to be present in 1-2% of males with leukemia. Due to the small sample size of this study 5% of 
male subjects were found to have testicular involvement. 
The risk classification of ALL in children is important in treatment decisions and therapeutic 
protocols and is determined by the initial white blood cell count at diagnosis; standard risk ALL 
includes subjects with an initial white blood cell count less than 50 000/microliter and high risk 
ALL includes subjects with an initial white blood cell count greater than 50 000/microliter. In 
this study 80% of subjects were diagnosed with standard risk ALL and 20 % with high risk ALL. 
All subjects within the high risk group were male. The comparison of these results with other 
studies is limited due to a lack of published studies. 
5.3. Cancer treatment  
At Sheikh Khalifa Medical City (SKMC), the ALL treatment protocols used are as per the 
guideline of The Children’s` Oncology Group (USA) and treatment involves 5 treatment phases, 
namely induction, consolidation, interim maintenance, delayed intensification and maintenance. 
The goal of induction treatment was to eradicate more than 99% of the initial leukemic cells 
present in the bone marrow in order to restore normal haemopoiesis. Induction treatment 
regimens at SKMC included the addition of glucocorticoids (prednisolone or dexamethasone), 
vincristine and a third drug (asparaginase, anthracycline or both). A three drug induction regime 
was used to treat most standard risk cases of ALL and children with high risk ALL was treated 
with four or more drugs during the induction phase.  
Literature by The Children’s Oncology Group (2015) reported the clinical remission rates in 
children to be between 96-99% on completion of induction treatment. In this study 90% of 
subjects achieved remission on completion of induction treatment. This finding was similar to 
that of Owens et al (2011) which reported a cure rate of pediatric ALL approaching 90%.  The 
Middle Eastern study conducted by Al-Mulla et al (2014) on 1150 pediatric patients with ALL 
reported the end of induction remission rate to be 96.6% which was slightly higher than the 
finding in this study. 
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Research by Maloney (2011) found a greater incidence in remission induction failure in Downs 
syndrome ALL patients than non- Downs syndrome ALL patients; in this study the subject with 
Downs syndrome ALL successfully achieved remission on completion of induction treatment.  
5.4. Nutrition screening 
The first step in the management of under-nutrition or over-nutrition was the identification of 
undernourished or over nourished patients or those at risk for developing malnutrition. Nutrition 
screening was generally carried out by those members of the nursing team at first contact with 
the patient. The tool used in screening should be quick, easy to complete and validated for use in 
a pediatric oncology setting (McCarthy et al, 2012). At Sheikh Khalifa Medical City the nutrition 
screening tool incorporated into the electronic patient record was not a validated tool which 
makes its use in the pediatric oncology setting unreliable and inconsistent in detecting patients at 
risk for malnutrition during each treatment session.   
5.5. Anthropometric measurements during treatment 
In this study anthropometric measurements for all subjects were recorded as z-scores for weight-
for-age, length/height-for-age and BMI-for-age on the World Health Organization (WHO) 
growth charts at diagnosis and at the start and end of each treatment phase. A growth 
abnormality was deemed significant if a subject`s z-score for any of the above mentioned 
anthropometric measurements, was found to be more than 2 standard deviations greater than or 
less than the appropriate mean. At diagnosis all subjects were of normal weight-for-age and one 
subject was found to be stunted, stunting is a measure of linear growth that reflects the 
cumulative effect of chronic malnutrition (Children’s Oncology Group, 2015). Weight 
fluctuations were evident during the different treatment phases as patients experienced treatment-
related side-effects during the different phases of treatment which had a negative impact on their 
nutrition status.  
In general, 5% of subjects were found to be underweight at diagnosis and at the end of interim 
maintenance phases when BMI-for-age z-scores was used. At the end of other treatment phases, 
subjects were found to display normal BMI-for-age z-scores. Collins et al (2010) citing Reilly et 
al (1999), a study of more than 1000 children in the United Kingdom with standard risk ALL at 
diagnosis, found that the BMI-for-age z-score provided a good measure for protein energy 
malnutrition. These investigators reported that approximately 7% of the children in their study 
were malnourished at diagnosis (BMI-for–age z-score less than -2). Literature published by 
Maldonado-Alcazar et al (2013) reported the prevalence of malnutrition at diagnosis in their 
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study to be 7% for children living in developed countries and 21-23% for children living in 
developing countries.  
With regards to overweight 5% of subjects were found to be overweight at diagnosis and  10% of 
subjects were found to be overweight at the end of induction and maintenance treatments. 
Literature by Tan et al (2010) on 53 pediatric patients diagnosed with ALL and undergoing 
chemotherapy treatment found a large number of patients in his study to be overweight rather 
than underweight, as shown by the percentile distribution of various anthropometric indices. The 
study by Tan et al (2010) also revealed an early trigger towards childhood obesity during the 
latter part of ALL treatment especially during the maintenance phase.  
Weights for age, height-for-age and BMI-for-age are considered as the most sensitive indices for 
growth in children (Selwood et al, 2010). In this study weight loss expressed as a percentage of 
body weight lost provided a more accurate estimate of the true significance of weight loss in 
subjects on cancer treatment (chemotherapy). A weight loss of greater than 5% of body weight 
over a period of one month was considered a sign of nutritional deprivation even when the 
patient was not classified as undernourished by anthropometric parameters (Bauer et al, 2011; 
Selwood et al, 2010; Jeejeebhoy and Keith, 2005).  It was therefore important to consider weight 
loss percentage in the assessment of obese or overweight patients as they would have to lose a 
great amount of body weight before they are classified as underweight by anthropometric cut off 
points, even though they may be in a negative nutritional balance during cancer treatment. The 
results of this study showed that subjects experienced the greatest weight loss percentage during 
the consolidation (80%) and interim maintenance (65%) phases of treatment. This was as a result 
of treatment-related side-effects such as low absolute neutrophil count, thrombocytopenia, 
anemia, diarrhea, allergic rash from a component of the chemotherapy, vomiting, fever and 
upper respiratory tract infection which had a profound effect on the subject`s nutritional intake 
leading to a nutritional deprivation. The interim maintenance phase of chemotherapy was found 
to be the most demanding phase of treatment in this study as subjects experienced the greatest 
number of treatment-related side-effects and least weight gain. This is in line with published 
literature from the Oncology Cancer Group (2015). 
Other possible reason for weight fluctuations in subjects in this study was explained by the use of 
steroids which formed part of the treatment; during the first phase of treatment (induction) 
patients received high daily dose of steroids to induce remission. Past studies have shown 
antileukaemic drugs such as prednisolone and dexamethasone to induce weight gain and fat 
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accumulation by increasing the appetite and energy intake in pediatric patients on cancer 
treatment ultimately leading to overweight and obesity (Tan et al, 2010 citing Murphy et al, 
2006; Ladas et al, 2005;  Reilly et al, 2001).  
After induction treatment steroid treatment became transient and was only administered on 
alternate weeks during the chemotherapy cycle. The data collection in this study was based on 
time intervals corresponding to chemotherapy phases and many patients were assessed during the 
on and off steroid phase. Therefore patients experienced phases of excessive intake when on 
steroids followed by reduced intake for the rest of the treatment.  
In this study subjects on treatment for ALL underwent changes in nutritional status as manifest 
by a reduction in growth, weight gain and weight loss. Several factors such as diet, treatment-
related side-effects of chemotherapy, high doses of steroids received during each treatment phase 
and a lack of physical activity were possible reasons for the changes in weight observed. 
5.6. Biochemistry during treatment 
Chemotherapy involves giving high doses of drugs to patients diagnosed with ALL in order to 
kill the cancer that exists within the bone marrow and also the central nervous system in order to 
prevent relapse (Oncology Cancer Group, 2015). Bone marrow toxicity was common in all 
subjects undergoing chemotherapy in this study during all cycles of treatment and presented as 
leukopenia (a decrease in white blood cells); thrombocytopenia (a decrease in platelets); 
pancytopenia (a decrease in all blood cells); anemia (a decrease in red blood cells) or neutropenia 
(a decrease in neutrophils). Most subjects received blood transfusions as per the treatment 
protocol when hemoglobin levels were below 80-90 g/L to prevent subjects from becoming 
severely immunocompromised. Hemoglobin levels were found to return to normal once 
treatment was stopped and normal bone marrow function returned.  
The liver function tests showed the damaging effect of treatment on the liver; all subjects 
displayed high liver enzyme values during the course of treatment as the liver was responsible 
for metabolizing the chemotherapeutic agents however the hepatotoxicity of these 
chemotherapeutic drugs was usually temporary and liver function was found to return to normal 
once the drugs were stopped.  
Renal function was also compromised as a result of the toxic effects of the chemotherapeutic 
drugs and the duration of treatment with short breaks between chemotherapy cycles. A full 
discussion on the detrimental effect of chemotherapy on the liver and kidneys goes beyond the 
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purpose of this study; however in order to interpret the results it was essential to take into 
consideration the functionality of these organs. 
In this study, the oncology team made use of serum albumin levels to assess the nutritional status 
of subjects. Chemotherapy and steroid treatment are also known to affect serum albumin levels 
and one must also bear in mind that an indirect relationship exists between inflammation and 
hypoalbuminemia. Inflammation is known to contribute to net protein loss in individuals as a 
result of catabolism; albumin levels have to therefore be analyzed in relation to C-reactive 
protein levels in order ascertain whether the low albumin levels are as a result of a poor 
nutritional status or as a result of inflammation (Selwood et al, 2010).  Although albumin was 
used as an indicator of poor nutritional status in this study, its use to detect a poor nutritional 
status in subjects was believed to be inappropriate. Serum prealbumin which is a more sensitive 
marker of nutritional status in children receiving chemotherapy was not tested during the entire 
course of chemotherapy and could be acknowledged as a limitation of this study.  
Blood glucose levels were obtained as part of the routine biochemical panel as transient 
hyperglycemia was a recognized side effect of corticosteroids and asparaginase use especially 
during induction treatment. Overweight and risk of overweight were also significant risk factors 
of transient hyperglycemia (Zhang et al, 2014; Robertson et al, 2009). Hyperglycemia was 
evident in 10% of subjects during the induction treatment and in 15% of subjects during the 
interim maintenance and maintenance treatment phases respectively. In some studies the use of 
high doses of steroids combined with L-asparaginase and intravenous fluids have been 
implicated in the prevalence of hyperglycemia during induction treatment (Dare et al, 2013). 
Glucocorticoids have also been positively linked to an increase in blood glucose levels in 
children on cancer treatment by increasing liver gluconeogenesis. Patient`s with Downs 
syndrome were also found to have a higher incidence of treatment-related hyperglycemia during 
induction chemotherapy; though the reason for this is unclear. In this study the subject with 
Downs syndrome ALL had one reported episode of hyperglycemia at the end of interim 
maintenance treatment.  
5.7. Clinical findings during treatment 
In this study subjects experienced a variety of treatment-related side-effects such as pain, nausea, 
vomiting, hair-loss, weight gain or weight loss, constipation, diarrhea, neutropenia during the 
course of treatment. Constipation resulted in a number of subjects as the result of narcotic drugs 
prescribed for pain control. A change in taste was a common complication of cancer treatment in 
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study participants. Most subjects complained of a metallic taste with protein-rich foods which 
negatively impacted on the nutritional status often resulting in the subject being enterally fed in 
order to maintain growth. 
Research by Skolin et al (2006) found chemotherapy -induced nausea, diarrhea and taste changes 
to occur during the induction and consolidation phases of treatment, in this study however 
nausea, diarrhea and taste changes were mostly reported during induction, consolidation and 
delayed intensification treatment. 
There were no reports of osteoporosis or osteomalacia in the electronic files of subjects included 
in this study. Research by Salim et al (2013) reported a reduction of bone mass in children with 
ALL at diagnosis and during the first 6 months of chemotherapy. The possible long-term side-
effects of corticosteroids and antiemetic were said to reduce the synthesis of collagen, causing a 
decrease in bone mass and an increase in bone loss which resulted in osteomalacia, osteoporosis 
and skeletal anomalies in children (Rosen et al, 2013). The prevalence of osteopenia and 
osteoporosis in children with ALL was noted during all phases of ALL treatment and throughout 
the post treatment period for up to age 20 years in the study by Salim et al (2014). In a similar 
study the fracture rate in children receiving treatment for ALL was reported to be 6 times more 
common than in healthy children of the same age (Salim et al, 2014 citing Rogalsky et al, 1986).   
5.8. Nutrition support during treatment   
Nutritional support can be defined as the provision of nutrients in place of or in addition to that 
provided by normal eating to ensure a balanced diet (Bauer et al, 2011). Adequate nutrition is an 
important concern in children with ALL as a good nutritional status helps them cope better with 
the side-effects of cancer therapy by decreasing their risk of developing infections which affects 
their growth, causes treatment delays and affects the overall quality of life (Nieuwoudt, 2011).  
In this study information on current dietary intake, home feeding patterns, quality and quantity of 
food and food preferences, feeding environment, food allergies and intolerances were obtained 
from parents and caregivers during initial hospitalization for the initiation of induction treatment 
and during all treatment phases in order to assess the nutritional intake of patients. Oral feeding 
was generally recommended as the first option of feeding especially for children with a low 
nutritional risk. Nutrition support in the form of oral nutritional supplements in conjunction with 
an age-appropriate diet or enteral feeding in combination with an age-appropriate diet was only 
initiated based on weight loss, severity of treatment-related side-effects which caused a decrease 
in oral intake. In general, patients experienced phases of excessive intake when on steroids 
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followed by a reduced intake for the rest of the course of treatment. During the first phase of 
treatment (induction) subjects were treated with a high daily dose of steroids in order to induce 
remission, this increased their appetites, and minimized the symptoms of nausea and vomiting. 
After remission (from the consolidation phase onwards) steroid therapy was transient.  
A few factors besides those directly related to the disease and its treatment such as unfamiliar 
foods and meal patterns, hospital routines, learned food aversions, feeding environment and meal 
timings also contributed to an inadequate food intake during the induction cycle. Subjects often 
had limited time to eat due to their treatment and investigation protocols coinciding with 
mealtimes. Extended periods of hospitalization especially during the induction phase resulted in 
subjects growing tired of the repetitive menus and they developed a food aversion to hospital 
meals. The Cancer and Leukemia in Childhood `Fit to eat` campaign which was launched in the 
United Kingdom as a result of parent complaints that hospital meals were unappealing, poorly 
prepared, not age-appropriate, lacked choice and was served cold or missed due to treatment and 
investigation protocols coinciding with mealtimes aimed at eliminating the inconsistencies in 
hospital food provision for children with cancer (Selwood et al, 2010). This campaign which was 
adopted by NHS hospitals in the United Kingdom are reviewing existing national nutritional 
guidelines to ensure that all children with cancer are given age-appropriate nutritious meals when 
they are in hospital.  
Children who receive treatment for long periods of time are known to be more prone to having 
poor appetites and diminished energy intakes as the medications used in chemotherapy alter taste 
perceptions which include sourness, bitterness or a metallic taste when consuming foods. 
Changes in taste were directly linked to the development of anorexia which was described as a 
major cause of malnutrition in patients on cancer treatment (Owens et al, 2013). In this study the 
highest incidence of anorexia was reported during interim maintenance treatment. It has been 
established in the literature that the interim maintenance phase of chemotherapy is the most 
demanding phase of treatment causing a number of treatment-related side-effects and the least 
weight gain in children. As previously mentioned subjects were found to have the highest weight 
loss percentages during the consolidation (80%) and interim maintenance (65%) phases of 
treatment. It could therefore be argued that a decreased daily energy intake combined with 
treatment-related side-effects was contributing factors in weight loss in these subjects. 
In some cases, the use of oral nutritional supplements as a means of nutrition support was started 
on a prophylactic or preventative basis rather than on a treatment basis for reasons of perceived 
 
 
 
 
  
81 
risk rather than actual risk. This study showed that a high proportion of subjects received some 
type of nutritional support (high calorie high protein diet and/ or oral nutritional supplements and 
/or enteral feeds) during the course of treatment in order to avoid nutritional depletion. Almost 
all subjects received at least one type of nutritional support during the entire course of treatment 
reflecting the intensity of the chemotherapy and duration of the treatment. The treatment could 
span around 2-3 years without much break between cycles in order to induce and maintain 
remission (Owens et al, 2013).  
At the end of induction treatment five of the twenty subjects were found to have a loss in weight 
with no change in stature; three of the five subjects had a weight loss greater than 5%. The 
families of two of the three subjects with significant weight loss agreed to nasogastric tube 
insertion to supplement the oral intake of the subjects and one family refused. At the end of 
interim maintenance treatment the two subjects on nasogastric tube feeds showed a positive gain 
in weight and stature; which warranted stopping the nasogastric tube feed. The subject whose 
family refused nasogastric tube insertion continued to lose weight and did not gain height during 
the remaining course of treatment.  
A study by Ijpma et al (2016) conducted on 60 adult patients with gastric cancer found the 
palatability of milk-based vanilla oral nutritional supplement to decrease over time, namely 
before, during and after chemotherapy; however the palatability of a milk based strawberry oral 
nutritional supplement was preferred before, during and after chemotherapy. It was therefore the 
recommendation of this study to offer a variety of types and flavors of oral nutritional 
supplements to malnourished cancer patients throughout the treatment period. In this study a 
variety of flavors of age-appropriate supplements were offered to subjects to prevent taste fatigue 
and improve acceptance. The vanilla flavored oral nutritional supplement was best tolerated by 
all subjects during the entire course of treatment. In light of this finding, more research is needed 
to investigate the taste and smell changes in pediatric cancer patients undergoing chemotherapy.   
Enteral feeding in the form of a nasogastric tube feed was commenced in subjects with 
suboptimal intake. Weight loss as a result of a poor oral intake and poor acceptance to an oral 
nutritional supplement was the main reasons for starting an enteral feed for subjects in this study. 
Jeejeebhoy and Keith (2005) and Sala et al (2004) supported enteral feeding of cancer patients 
and also mentioned the enteral route to be more practical, have a lower risk of infection and safer 
(maintains gut integrity and reduces the risk of bacterial translocation). Parenteral nutrition was 
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not prescribed as route for nutrition support in subjects in this study, as all subjects had normal 
gastrointestinal function. 
During the consolidation, interim maintenance, delayed intensification and maintenance cycles 
of treatment nutrition intervention sessions with the dietitian were missed due to the multitude of 
tests, procedures and visits of subject`s to other specialties. During the above mentioned 
treatment cycles subjects were only referred to the dietitian service if they were to be started on 
an oral nutritional supplement or already receiving an oral nutritional supplements or were to 
start an enteral feed.  
In summary it has been widely recognized in the literature that the nutritional status of a child is 
likely to be affected by cancer at some point during the disease. The results of this study showed 
that some phases of treatment may increase the risk for weight loss. In this study pediatric 
subjects on treatment for ALL underwent changes in nutritional status as manifest by a reduction 
in growth, weight gain and weight loss. Although the anthropometric z-scores did not 
significantly change between diagnosis and the end of treatment, the percentage weight loss of 
patients during cycles was significant. Malnutrition in children with cancer should not be 
accepted or tolerated as an unavoidable process at any stage of the disease. Early nutrition 
intervention should be considered to prevent weight loss or excessive weight gain as a result of 
treatment-related complications and all nutritional concerns should be measured within the 
perspective of the child`s growth and development. Social and emotional issues also need to be 
addressed during and after treatment to ensure that children with cancer can function normally 
within the school system and society at large. Although the sample of subjects in this study was 
small it showed that the growth of children with ALL in the United Arab Emirate has a pattern 
different to that in most developing countries where malnutrition is common. More research is 
needed within the context of the United Arab Emirates to analyze the impact of nutrition 
intervention strategies during treatment on the morbidity, mortality and quality of life of 
pediatric cancer survivors. 
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THE DEVELOPMENT OF A NUTRITION SUPPORT PROTOCOL 
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The development of a nutrition support protocol  
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy treated at 
Sheikh Khalifa Medical City (SKMC). Patients on treatment (chemotherapy) for ALL developed 
numerous physical, medical and nutrition related conditions as a result of the treatment which 
affected their tolerance to meals and feeds. This made nutritional support extremely challenging.  
In this study treatment delays between treatment phases occurred as a result of neutropenia, 
diarrhea, skin rash, fever, vomiting, thrombocytopenia, upper respiratory tract infection and 
elevation in liver enzymes. The most common reasons for treatment delays between treatment 
phases were neutropenia, diarrhea and fever. At the start of consolidation treatment 40% of 
subjects experienced a delay; at the start of interim maintenance treatment 30% of subjects 
experienced a delay; at the start of delayed intensification 10% of subjects experienced a delay 
and at the start of maintenance treatment 20% of subjects experienced a delay.  
Subjects also experienced the greatest number of treatment-related complications during the 
induction, consolidation, interim maintenance and delayed intensification phases of treatment 
and the lowest number during the maintenance phase. During the induction phase the most 
common nutritionally related complications were appetite changes, nausea, vomiting, diarrhea, 
anorexia, hyperglycemia, taste changes, tumor lysis syndrome and constipation. During the 
consolidation phase the most common nutritionally related complications were appetite changes, 
nausea, vomiting, diarrhea, anorexia, taste changes, constipation, mucositis, stomatitis and 
pharyngitis. During the interim maintenance phase the most common nutritionally related 
complications were appetite changes, nausea, vomiting, diarrhea, anorexia, taste changes, 
constipation, mucositis and stomatitis. During the delayed intensification phase the most 
common nutritionally related complications were appetite changes, vomiting, diarrhea, anorexia, 
taste changes, constipation, mucositis and stomatitis. During the maintenance phase there was an 
absence of nutritionally related complications.   
In this study, subjects often experienced a lack of appetite which was exacerbated by nausea, 
vomiting, mucositis, stomatitis, taste changes, constipation, diarrhea and metabolic 
abnormalities. Nutrition support in the form of a high calorie high protein diet with snacks and / 
or the addition of a standard or high calorie high protein age-appropriate oral nutritional 
supplement and/ or the introduction of a nasogastric tube feed either as a sole source of nutrition 
or as an overnight feed was initiated when a subject showed signs of weight loss as a result of the 
treatment. Total parenteral nutrition was not prescribed for any subjects in this study as subjects 
 
 
 
 
  
85 
responded well to dietary supplementation with oral nutrition supplements and enteral feeds. 
Nutrition support was also not initiated in subjects who were able to maintain normal growth 
during treatment. To date there are no universally agreed criteria for the duration of nutrition 
support, timing and type of formula composition for use in pediatric oncology due to the broad 
scale of the disease and complexity of treatment modalities and their side-effects (Bauer et al, 
2011). 
In this study the distribution of anthropometric z-scores found the highest percentage of stunting 
during the start and end of consolidation (10%) and interim maintenance treatment (10%). There 
was a low percentage of underweight during all phases of treatment. The highest percentage of 
overweight was at the start (10%) and end (10%) of induction treatment and at the end of 
maintenance treatment (10%). Weight loss expressed as a percentage of body weight provided a 
more accurate estimate of the true significance of weight loss in subjects during cancer treatment 
(chemotherapy) in this study. A weight loss of greater than 5% of body weight over a period of 
one month is considered a sign of nutritional deprivation even when the subject is not classified 
as undernourished by anthropometric parameters (Bauer et al, 2011; Jeejeebhoy and Keith, 
2005).  At the end of the induction phase 15% of subjects lost more than 5% of their body 
weight; at the end of consolidation treatment 40% of subjects lost more than 5% of their body 
weight; at the end of the interim maintenance treatment 25% of subjects lost more than 5% of 
their body weight and at the end of the delayed intensification and maintenance phases of 
treatment none of subjects lost more than 5% of their body weight. 
From the results of this study a significant improvement in weight was observed during the 
induction, consolidation, interim maintenance and delayed intensification phases of treatment as 
a result of nutritional support in the form of an oral nutritional supplement and or an enteral feed. 
Aggressive nutritional support in the form of enteral feeding enabled subjects who experienced a 
significant weight loss during the second phase of treatment (consolidation) to successfully reach 
normal growth centiles during the third stage (interim maintenance) and forth stage of treatment 
(delayed intensification). A significant improvement in the longitudinal growth was also 
observed in subjects during the interim maintenance, delayed intensification and maintenance 
phases of treatment at initiation of nutritional support in the form of enteral feeds. This suggests 
the positive effect of nutritional support in preventing further nutritional depletion and 
counteracting undernutrition per se.  
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Within the health care environment it is common practice for dietitians to document the positive 
outcomes of the medical nutrition therapy they provide so as to develop nutrition protocols to 
standardize the nutrition practice guidelines within similar populations. The main aim of this 
nutrition support protocol is to assist healthcare professionals involved in the management of 
pediatric cancer (ALL) to optimize the nutritional status of patients by using clinical experience 
and evidence based guidelines alongside accepted best practice in order to maximize treatment 
outcomes and enhance the quality of life of these patients. Figure: 1 below illustrates a nutrition 
support protocol for the management of Acute Lymphoblastic Leukemia in childhood. 
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Figure: 1 A nutrition support protocol for the Management of Acute Lymphoblastic Leukemia in Childhood. 
Low nutritional risk High nutritional risk 
Normal –calorie, normal-protein diet & monitoring Refer to Dietitian 
Gut functioning 
Yes  No 
TPN. Implement TPN monitoring criteria 
 
High calorie high protein diet with or without oral nutritional supplements 
Decline in nutritional status due to treatment side-effects 
Improvement in nutritional status 
No  
Yes 
Yes No 
Continue diet prescription & monitor 
Yes  No 
Continue with diet prescription and monitor Consider overnight enteral feeding 
Diagnosis 
Nutrition screening 
Improvement in nutritional status 
No  Yes 
Consider enteral feeds as sole source of nutrition 
nutrition 
Improvement in nutritional status 
Poor tolerance to enteral feed, consider use of 
hydrolyzed or amino acid-based formula or feed 
Improvement in nutritional status 
Continue with diet prescription and monitor 
Continue with diet prescription and monitor Implement TPN with monitoring criteria 
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In order to accomplish this task the nutrition protocol needs to provide the necessary tools for 
nutrition management which includes screening, assessment, intervention and evaluation. 
Early identification of undernourished patients from diagnosis and throughout the length of the 
treatment process can be accomplished by nutritional screening (Bauer et al, 2011).  
Nutrition screening tool   
In 2015 a screening tool for childhood cancer called SCAN was developed and validated for use 
in this population by Murphy et al. Incorporation of this tool into the patient`s electronic medical 
record at SKMC will improve the screening of each subject at diagnosis and during each 
treatment visit to ensure that the nutrition interventions in place are suitable and effective. The 
early identification of nutritional risk is paramount in providing a high standard of nutrition care 
that can often prevent the need for more aggressive nutritional support later during the treatment 
phase. In order for a validated screening tool to be effective updated anthropometric 
measurements for weight and height is of paramount importance during each outpatient or 
treatment visit. 
Nutrition assessment  
Current methods of assessing the nutritional status of children involve the following (Nieuwoudt, 
2011; Ladas et al, 2005): 
 Anthropometry: a combination of objective anthropometry (weight, height, BMI). 
 Biochemical and immunologic measurements (visceral proteins (prealbumin, transferrin 
and retinol binding protein); blood glucose levels; hemoglobin; hematocrit; lymphocyte 
count; lipid profiles) 
 Clinical assessment to find signs and symptoms of nutrient deficiencies or excesses (the 
absence or presence of oedema, cachexia, obesity, skin changes, dry mucous membranes, 
petechiae or ecchymoses, healing of wounds, glossitis, stomatitis and cheilosis and the 
evaluation of body composition- including fat and muscle stores). 
 Dietary history (home feeding regimes, food preferences, types and textures, food 
allergies, food intolerances, feeding environment, problems when chewing or 
swallowing, religious and cultural food habits, feeding skills of the child based on the 
child`s age, stooling habits). 
Once a patient has been screened, assessed and his/her nutrition risk has been determined the 
nutritional care protocol will be followed. If a subject is at high nutritional risk early nutritional 
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intervention will be considered to prevent further weight loss and nutritional deterioration. The 
decision for nutritional support will involve discussion with the multidisciplinary team, the 
dietitian and the family of the subject. The level of intervention will vary depending on the 
individual subject`s nutritional status. Further nutrition support may be accomplished in the 
following ways to maintain body stores as close to ideal as possible, minimize weight loss and 
promote appropriate age related growth and development: by oral intake (diet alone or a 
combination of diet + oral nutritional supplement); by enteral nutrition and by parenteral 
nutrition. 
Oral intake 
Oral feeding will be recommended as the first method of choice especially for ALL subjects with 
a low nutritional risk. This will involve individualized meal plans to accommodate personal food 
preferences to achieve realistic achievable nutritional goals. Nutrition education on age-
appropriate, energy dense foods (based on the subject`s culture and traditions) will be provided 
to caregivers. If a subject`s oral intake deteriorates during treatment the introduction of small 
frequent meals, in addition to an oral nutritional supplement will be considered. There is a wide 
range of oral nutritional supplements available in a variety of styles (milk based or juice based or 
as a milkshake) and flavors and energy densities (1 kilocalorie per milliliter or 1.5 kilocalorie per 
milliliter).  
In some cases, the modification of food textures maybe required to facilitate chewing and 
swallowing to accommodate mucositis and stomatitis (side-effects of cancer treatment). Dry 
mouth and changes in taste perception may affect oral intake of meals and snacks. Excessive 
weight gain as a result of steroid treatment may develop; nutrition education on healthy eating 
should be shared with the family to enable them to provide the subject with healthy meals and 
snacks. 
Enteral feeding 
Enteral feeding will be provided for those subjects with suboptimal intake and a normal 
gastrointestinal tract. Subjects with swallowing difficulties or mucositis will be fed with the use 
of a nasogastric tube for duration of up to 3 weeks or by a gastrostomy tube if the duration of 
feeding is expected to be greater than 3 weeks. Feeds maybe administered as a continuous feed 
(18 or 20 hours) or as bolus feeds every 3 to 4 hours or at night only so as to maintain an oral 
intake during the day. Enteral feeding is always considered to be more practical and safe in 
children with cancer than parenteral nutrition regimes.   
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The recommended criteria for starting enteral feeding according to Bauer et al (2011) are: 
 Weight two centiles below height centile.  
 Percentage weight for height < 90% of the ideal. 
 Decrease in current percentiles for weight or height of two centiles. 
 Total weight loss > 5% since diagnosis. 
 Reduced oral intake of < 70% of estimated average requirement for > 5 days. 
Enteral nutrition as a sole source of nutrition or as an overnight enteral feed has been found to be 
safe and effective in the home environment for pediatric cancer patients who are unable to 
consume an adequate oral diet. It also has a lower risk for infection, preserves gut integrity and 
reduces bacterial translocation and is thus recommended since it is more practical and safer than 
parenteral nutrition (Bauer et al, 2011 citing Rickard et al, 1986). Multiple studies have found 
success in improving the nutritional status of children by means of nasogastric tube feeds, during 
intensive cancer treatments including bone marrow transplantation with minimal complications 
(Selwood et al, 2011 citing De Swarte-Wallace et al, 2001; Pietsch et al, 2000; den Broeder et 
al, 1998).  
Enteral formulas containing intact protein was reported to be well tolerated by children during 
chemotherapy however following chemotherapy protein hydrolysate and amino acid based 
formulas were found to be better tolerated as children as children may display reduced 
gastrointestinal motility with a risk for malabsorption (Selwood et al, 2011 citing Ward, 2003).  
Nasogastric and nasoduodenal feeding is recommended for short duration feeding as these 
feeding devices cause nasal discomfort, recurrent pulmonary aspiration and easy tube 
dislodgment El- Matary, 2008). For long duration feeding, gastrostomy (a feeding tube which is 
inserted directly into the stomach through an opening in the anterior abdominal wall) or 
jejunostomy (a tube inserted directly into the small intestine) feeding tubes are recommended.  
The side-effects of cancer treatments such as nausea, vomiting and diarrhea pose limitations to 
the use of enteral nutrition support in cancer patients however the use of prokinetic agents and 
post pyloric feeding has been reported in the literature to minimize vomiting (Barbosa et al, 
2012). Enteral nutrition is discouraged in cancer patients with mucositis and enteral tube 
insertion is not recommended in children with neutropenia or thrombocytopenia as these children 
have an increased risk of bleeding during feeding tube insertion (El- Matary, 2008). A study 
conducted by Barbosa et al (2012) found malnourished children with cancer to show improved 
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growth parameters, in terms of z-scores for weight-for-age and BMI, with initiation of enteral 
nutrition during cancer treatment.  
Total parenteral Nutrition  
Total parenteral nutrition is recommended for those subjects whose enteral feeding regimes 
cannot provide adequate nutrition. A risk benefit analysis needs to be performed to justify the use 
of parenteral nutrition in cancer subjects because of its life threatening complications. The choice 
of central versus peripheral parenteral nutrition depends on the length of therapy. Peripheral 
parenteral nutrition is recommended for short term therapy which usually lasts between 7 to 10 
days. Parenteral nutrition therapy requires more monitoring than enteral nutrition and carries the 
highest incidence of septic complications (Nieuwoudt, 2011). Most studies aiming to assess the 
effectiveness of TPN in pediatric cancer patients have found a positive effect on reversing 
malnutrition during the initial phase of treatment (Andrassy et al, 1998; Rickard et al, 1986; 
Donaldson et al, 1982). TPN is however associated with liver disease which remains a dreaded 
complication of parenteral nutrition in children and the risk of refeeding syndrome remains a 
serious complication in aggressive nutritional rehabilitation (by the enteral and/or the parenteral 
route) in severely malnourished children with cancer (Nieuwoudt, 2011).  
Once the nutrition support plan has been implemented a plan for monitoring is vital in order to 
evaluate the effectiveness of the nutrition support. Nutrition screening is also important during 
all phases of treatment to ensure that the nutrition support plan in place meets the nutritional 
goals of the patient. Weight and height measurements should be updated during each outpatient 
visit to reassess the ongoing nutritional status of the patient.  
In conclusion numerous factors must be considered when addressing the nutritional concerns of 
pediatric cancer patient. This nutrition support protocol, if approved by the pediatric healthcare 
team at SKMC, will serve as an important tool to improve the quality of care of children on 
cancer therapy.  
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7.1. Conclusion  
It has been widely recognized in the literature that the nutritional status of a child is likely to be 
affected by cancer at some point during the disease. The results of this study showed that some 
phases of treatment may increase the risk for weight loss. In this study pediatric subjects on 
treatment for ALL underwent changes in nutritional status as indicated by a reduction in growth, 
weight gain and weight loss. Although the anthropometric z-scores did not significantly change 
between diagnosis and the end of treatment, the percentage weight loss of patients during cycles 
was significant. Malnutrition in children with cancer should not be accepted or tolerated as an 
unavoidable process at any stage of the disease. Early nutrition intervention should be considered 
to prevent weight loss or excessive weight gain as a result of treatment-related complications and 
all nutritional concerns should be measured within the perspective of the child`s growth and 
development. Social and emotional issues also need to be addressed during and after treatment to 
ensure that children with cancer can function normally within the school system and society at 
large. Although the sample of subjects in this study was small it showed that the growth of 
children with ALL in the United Arab Emirate has a pattern different to that in most developing 
countries where malnutrition is common. More research is needed within the context of the 
United Arab Emirates to analyze the impact of nutrition intervention strategies during treatment 
on the morbidity, mortality and quality of life of pediatric cancer survivors. 
7.2. Recommendations 
Cancer during childhood can negatively affect a child`s ability to achieve normal growth and 
development. In this study cancer treatment in the form of chemotherapy independently affected 
a child`s nutritional status during stages of treatment. Undernutrition during cancer treatment can 
increase morbidity and mortality (Ladas et al, 2005) which in turn decreases the quality of life by 
increasing hospital admission. On the other hand, over nutrition during cancer treatment has been 
found to increase the risk of morbidity, mortality and chemo induced toxicity (Tan et al, 2013). 
Appropriate nutritional care, comprising nutritional assessment and nutritional intervention, is 
therefore becoming increasingly important to maintain optimal growth and development during 
all stages of cancer treatment. 
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7.2.1. Nutrition screening tool 
In children the first measurable sign of undernutrition is a decrease in body weight. It is therefore 
pivotal that during cancer treatment undernutrition be promptly detected and treated so as to 
avoid changes in the normal growth and development of a child. 
The first step in the management of malnutrition is the prompt detection of patients who are 
malnourished or at risk for malnutrition through the process of nutritional screening. Nutritional 
screening is generally carried out by members of the nursing team at first contact with the patient 
(McCarthy et al, 2012). The tool used for screening should be quick, simple to complete and 
validated for use in children with cancer. To date there is only one nutrition screening tool called 
SCAN which has been designed and validated to detect undernutrition in children with cancer. 
However this tool cannot be used to detect patients at risk for obesity during cancer treatment 
(Murphy et al, 2015). 
At Sheikh Khalifa Medical City (SKMC) the nutrition screening tool currently incorporated into 
the electronic pediatric patient chart has not been validated for use in children which makes it an 
inaccurate and unreliable tool in detecting the nutritional risk of pediatric patients receiving 
treatment. This is a limiting factor for improving the nutritional support of children on cancer 
treatment. It is therefore recommended that the Nutrition Screening Tool for Childhood Cancer 
(SCAN) be incorporated in to the electronic patient record at SKMC to improve the nutrition 
screening process. Nutritional risk screening is essential for the care of pediatric cancer patients 
at diagnosis and at regular intervals (start and end of each phase of treatment) in order to identify 
children at risk.  
7.2.2. Anthropometric measurements 
The most sensitive indices for growth in children include weight and height-for-age and body 
mass index. In this study, growth was assessed by extrapolation of recorded weight and height 
data from the WHO growth charts within the electronic medical record at diagnosis and at the 
start and end of each treatment phase. Updated weight and height measurements are required 
throughout the duration of treatment in order to accurately assess the patient`s growth. It has 
been noted that in this study more attention was given to recording an updated weight than a 
height; as chemotherapy drug doses are based on a patient`s weight rather than height.  
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7.2.3. Nutrition support 
Nutrition support is initiated based on the results of the nutritional assessment which includes 
weight loss, excessive weight gain, nutritional intake and the gastrointestinal side-effects of the 
cancer treatment. This study showed that a high proportion of patients experienced a multitude of 
treatment-related side-effects which affected their oral intake; nutritional support was therefore 
initiated in order to prevent nutrition depletion. This observation reflected the need for a nutrition 
support protocol for patients on cancer treatment once malnutrition has been identified. Figure 1 
above was developed based on the results and experience obtained with the study.   
7.2.3. Cook to order service  
The food service delivery system in use at SKMC does not provide suitable age-appropriate 
meals and flexibility in meal timings to meet the individual needs of a child with cancer. This 
leads to a high level of dissatisfaction with food provision to children with cancer in hospital. In 
order to address these inconsistencies in food provision to children with cancer in hospital it is 
recommendation of this study to provide a `cook to order service` which allows patients to order 
meals off a `room service menu throughout the day to accommodate treatment timings, food 
preferences and child friendly portion sizes to suit each age group and appropriate crockery and 
cutlery for children. The oncology dietitian will need to work closely with the chef to discuss the 
individual needs of the children on cancer treatment and would help the oncology dietitian to re-
channel her resources towards more appropriate referrals than completing menus with personal 
food preferences.  
7.2.4. Biochemistry  
It is recommended that a test for prealbumin be added to the routine laboratory tests completed at 
the start and end of each phase of treatment. Medical staff working in pediatric oncology will 
need to be educated on the benefits of using prealbumin versus albumin as a marker for 
nutritional status as serum albumin levels do not reflect recent dietary intake and may be found 
to be normal in patients with severe protein energy malnutrition. Prealbumin is a more sensitive 
marker to assess the nutritional status of children receiving chemotherapy as chemotherapeutic 
drugs have the ability to negatively affect the nutritional intake of a child within a short time of 
starting chemotherapy. 
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7.2.5. Food diary 
The use of a three day food record diary is recommended to accurately assess the dietary intake 
of pediatric patients on cancer treatment during the consolidation, interim maintenance and 
delayed intensification and maintenance cycles when patients are at home. The food dairy will be 
useful to the caregiver as it does not rely on his or her memory to recollect the dietary intake of 
the child between treatment sessions and it will be useful to the dietitian/healthcare professional 
during the nutrition assessment session to obtain a realistic view of the patient`s actual intake 
versus perceived intake. The food dairy will allow the dietitian to correctly assess and validate 
the dietary intake of a child on treatment for cancer.  
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CHAPTER 8 
LIMITATIONS OF THE STUDY 
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Limitations of the study 
Although this retrospective study has reached its aim there were some unavoidable limitations. 
This chapter discusses the limitations of this study.  
8.1. Sample size 
The first limitation was the sample size. Although all patients included in the study have the 
same type of cancer, have undergone cancer treatment under the same protocols and policies and 
data gathering are the same; the sample size was small. A larger sample size with a multicenter 
approach is needed for better understanding of the effect of ALL on the nutritional status of 
children undergoing treatment in the United Arab Emirates.  
8.2. Study Design 
The second limitation was the study design. In this study a retrospective study design was used 
to collect data from electronic patient medical records as it is less expensive to conduct since 
outcome and exposure has already occurred and the resources are mainly directed at data 
collection and analysis. A major disadvantage of this type of study design is that the outcome 
assessment cannot be controlled and therefore has to rely on others for record keeping. This 
study was therefore limited by the detail of anthropometric measurements obtained from 
electronic patient chart review. Although a hospital protocol exists for routine growth 
measurements (weight, length/height, head circumference) not all of these were routinely 
measured by staff. In particular length/height and head circumference was not routinely 
measured as inpatients receiving induction chemotherapy or as outpatients on their routine visits 
to receive chemotherapy. Weight measurements were seen as the main priority as the weight of a 
patient was needed to determine the appropriate drug dose for chemotherapy; the accuracy of 
length measurements recorded in the electronic patient records during treatment was therefore 
questionable.  
8.3. Diet history 
The third limitation of this study was the information pertaining to the dietary intake of a patient 
prior to diagnosis and during treatment (consolidation, interim maintenance, delayed 
intensification and maintenance treatment).  In this study information on current dietary intake, 
home feeding patterns, quality and quantity of food, food preferences, feeding environment, food 
allergies and intolerances were obtained from parents and caregivers during initial 
hospitalization to start induction treatment and during each treatment session. Self-reporting of 
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dietary intake was limited by the individual`s memory and the emotional influence of the disease 
on the caregiver. Post remission most parents and caregivers were apprehensive about the 
patient’s nutritional intake as they wanted to avoid the child`s hospitalization for further 
evaluation as it was emotionally overwhelming for the family. 
8.4. Serum albumin  
The forth limitation of this study was the use of serum albumin levels as an indicator of 
nutritional status. Many studies reject albumin as an indicator of nutritional status due to its long 
half-life of 20 days. Low albumin levels may occur in patient`s undergoing treatment as a result 
of the chemotherapy and/ or use of corticosteroids. Serum albumin levels can also be affected by 
many other factors besides nutrition such as inflammation, all of which result in a low sensitivity 
and specificity to changes in nutritional intake. Inflammation is known to contribute to a net 
protein loss as a result of catabolism therefore albumin levels must be analyzed in relation to C-
reactive protein levels in order ascertain whether the low albumin levels are as a result of a poor 
nutritional status or as a result of inflammation.   
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APPENDIX I: Letter to Institutional review board research Ethics Committee 
Looventharee Pillay 
Senior Dietitian  
Sheikh Khalifa Medical City 
PO Box 767879 
Abu Dhabi, UAE 
17 May 2015 
 
The Chairperson  
The Institutional Review Board Research Ethics Committee 
Sheikh Khalifa Medical City, Managed by Cleveland Clinic 
PO Box 51900 
Abu Dhabi, UAE 
 
RE: Letter of Request to conduct research at Sheikh Khalifa Medical City  
Dear Sir / Madam 
I am currently a final year MSc student at the University of Western Cape (South Africa). As 
part of the fulfillment of my degree I will need to complete a research project and write it up as a 
thesis. I wish to apply for permission to conduct this research at SKMC. The topic of my study is 
to investigate the nutritional status of children between the ages of 1-14 years old who have been 
newly diagnosed with acute lymphoblastic leukemia. I wish to conduct a retrospective study by 
reviewing anthropometric measurements (weights and heights) of patients from the electronic 
patient charts. The purpose of my study is to develop a comprehensive nutritional care program 
for patients diagnosed with acute lymphoblastic leukemia at Sheikh Khalifa medical City. 
I am looking forward to receiving a positive response towards my request. 
Thank You 
Kind Regards   
 
Looventharee Pillay     
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APPENDIX II: Approval letter from Institutional review board research Ethics Committee 
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APPENDIX III: Approval from UWC Ethics Committee to conduct the research 
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APPENDIX IV: Data Collection Form 
Patient Number:  
Gender (circle):             Male             Female 
Cancer Diagnosis:        Acute Lymphoblastic Leukemia (ALL) 
                                       High risk    Y N       Low Risk    Y N 
Date of Birth:          dd/mm/yyyy                                         
Age at diagnosis:     in years and months                             
Date of diagnosis:    dd/mm/yyyy                                        
 
Anthropometrics: 
 
WHO growth 
charts 
Admission 
 
Date|: 
Age: 
Induction 
 
Date: 
Age: 
Consolidation 
 
Date: 
Age: 
Delayed 
Intensification 
Date: 
Age: 
Maintenance 
  
Date: 
Age: 
Weight (kg) 
Wt-for-age 
z-score 
     
Height (cm) 
Ht-for-age 
z-score 
     
HC (cm) 
HC for age 
z-score 
     
Wt-for-Ht 
z-score 
     
BMI-for-age 
z- score 
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Laboratory values:  
 
 Admission 
 
Date: 
Induction 
 
Date: 
Consolidation 
 
Date: 
Delayed 
Intensification 
Date: 
Maintenance 
 
Date: 
Creatinine 
(micromole/L) 
     
Urea (mmol/L):      
Total protein (g/L)      
Albumin (g/L)      
MCV (fL):      
MCH (pg):      
MCHC (g/L):      
Platelets      
WBC      
RBC      
Hgb (g/L) 
 
     
Hematocrit (L/L)      
Neutro (%)      
Lymph (%)      
Mono (%)      
Blasts (%)      
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Nutrition Intervention: 
Has patient received nutrition education /intervention /support at diagnosis?       Y       N 
(If so, please describe): 
 
Date  
 
Intervention (education, dietary intervention, nutritional support) 
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APPENDIX V: Excel Spread Sheet for Data Analysis  
 
 
 
 
 
 
